<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease - Poole, P - 2019 | Cochrane Library</title> <meta content="Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease - Poole, P - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001287.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease - Poole, P - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001287.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001287.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Phillippa Poole" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Kavin Sathananthan" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Rebecca Fortescue" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="rnormans@sgul.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD001287.pub6" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/05/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001287.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001287.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001287.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bronchitis, Chronic [*drug therapy, prevention &amp; control]; Disease Progression; Expectorants [*therapeutic use]; Pulmonary Disease, Chronic Obstructive [*drug therapy, prevention &amp; control]; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001287.pub6&amp;doi=10.1002/14651858.CD001287.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="z6k50IFd";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001287\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001287\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","ms","zh_HANS","fa","de"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001287.pub6",title:"Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease",firstPublishedDate:"May 20, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001287.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001287.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001287.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001287.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001287.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001287.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001287.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001287.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001287.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001287.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15772 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001287.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-sec-0107"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-sec-0099"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/appendices#CD001287-sec-0112"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/table_n/CD001287StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/table_n/CD001287StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/information#CD001287-cr-0002">Phillippa Poole</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/information#CD001287-cr-0003">Kavin Sathananthan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001287.pub6/information#CD001287-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Rebecca Fortescue</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/information/en#CD001287-sec-0131">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 May 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001287.pub6">https://doi.org/10.1002/14651858.CD001287.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001287-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001287-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001287-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001287-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001287-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001287-abs-0001" lang="en"> <section id="CD001287-sec-0001"> <h3 class="title" id="CD001287-sec-0001">Background</h3> <p>Individuals with chronic bronchitis or chronic obstructive pulmonary disease (COPD) may suffer recurrent exacerbations with an increase in volume or purulence of sputum, or both. Personal and healthcare costs associated with exacerbations indicate that therapies that reduce the occurrence of exacerbations are likely to be useful. Mucolytics are oral medicines that are believed to increase expectoration of sputum by reducing its viscosity, thus making it easier to cough it up. Improved expectoration of sputum may lead to a reduction in exacerbations of COPD. </p> </section> <section id="CD001287-sec-0002"> <h3 class="title" id="CD001287-sec-0002">Objectives</h3> <p><b>Primary objective</b> </p> <p>• To determine whether treatment with mucolytics reduces exacerbations and/or days of disability in patients with chronic bronchitis or COPD </p> <p><b>Secondary objectives</b> </p> <p>• To assess whether mucolytics lead to improvement in lung function or quality of life </p> <p>• To determine frequency of adverse effects associated with use of mucolytics</p> </section> <section id="CD001287-sec-0003"> <h3 class="title" id="CD001287-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register and reference lists of articles on 12 separate occasions, most recently on 23 April 2019. </p> </section> <section id="CD001287-sec-0004"> <h3 class="title" id="CD001287-sec-0004">Selection criteria</h3> <p>We included randomised studies that compared oral mucolytic therapy versus placebo for at least two months in adults with chronic bronchitis or COPD. We excluded studies of people with asthma and cystic fibrosis. </p> </section> <section id="CD001287-sec-0005"> <h3 class="title" id="CD001287-sec-0005">Data collection and analysis</h3> <p>This review analysed summary data only, most derived from published studies. For earlier versions, one review author extracted data, which were rechecked in subsequent updates. In later versions, review authors double‐checked extracted data and then entered data into RevMan 5.3 for analysis. </p> </section> <section id="CD001287-sec-0006"> <h3 class="title" id="CD001287-sec-0006">Main results</h3> <p>We added four studies for the 2019 update. The review now includes 38 trials, recruiting a total of 10,377 participants. Studies lasted between two months and three years and investigated a range of mucolytics, including N‐acetylcysteine, carbocysteine, erdosteine, and ambroxol, given at least once daily. Many studies did not clearly describe allocation concealment, and we had concerns about blinding and high levels of attrition in some studies. The primary outcomes were exacerbations and number of days of disability. </p> <p>Results of 28 studies including 6723 participants show that receiving mucolytics may be more likely to be exacerbation‐free during the study period compared to those given placebo (Peto odds ratio (OR) 1.73, 95% confidence interval (CI) 1.56 to 1.91; moderate‐certainty evidence). However, more recent studies show less benefit of treatment than was reported in earlier studies in this review. The overall number needed to treat with mucolytics for an average of nine months to keep an additional participant free from exacerbations was eight (NNTB 8, 95% CI 7 to 10). High heterogeneity was noted for this outcome (I² = 62%), so results need to be interpreted with caution. The type or dose of mucolytic did not seem to alter the effect size, nor did the severity of COPD, including exacerbation history. Longer studies showed smaller effects of mucolytics than were reported in shorter studies. </p> <p>Mucolytic use was associated with a reduction of 0.43 days of disability per participant per month compared with use of placebo (95% CI ‐0.56 to ‐0.30; studies = 9; I² = 61%; moderate‐certainty evidence). With mucolytics, the number of people with one or more hospitalisations was reduced, but study results were not consistent (Peto OR 0.68, 95% CI 0.52 to 0.89; participants = 1788; studies = 4; I² = 58%; moderate‐certainty evidence). Investigators reported improved quality of life with mucolytics (mean difference (MD) ‐1.37, 95% CI ‐2.85 to 0.11; participants = 2721; studies = 7; I² = 64%; moderate‐certainty evidence). However, the mean difference did not reach the minimal clinically important difference of ‐4 units, and the confidence interval includes no difference. Mucolytic treatment was associated with a possible reduction in adverse events (OR 0.84, 95% CI 0.74 to 0.94; participants = 7264; studies = 24; I² = 46%; moderate‐certainty evidence), but the pooled effect includes no difference if a random‐effects model is used. Several studies that could not be included in the meta‐analysis reported high numbers of adverse events, up to a mean of five events per person during follow‐up. There was no clear difference between mucolytics and placebo for mortality, but the confidence interval is too wide to confirm that treatment has no effect on mortality (Peto OR 0.98, 95% CI 0.51 to 1.87; participants = 3527; studies = 11; I² = 0%; moderate‐certainty evidence). </p> </section> <section id="CD001287-sec-0007"> <h3 class="title" id="CD001287-sec-0007">Authors' conclusions</h3> <p>In participants with chronic bronchitis or COPD, we are moderately confident that treatment with mucolytics leads to a small reduction in the likelihood of having an acute exacerbation, in days of disability per month and possibly hospitalisations, but is not associated with an increase in adverse events. There appears to be limited impact on lung function or health‐related quality of life. Results are too imprecise to be certain whether or not there is an effect on mortality. Our confidence in the results is reduced by high levels of heterogeneity in many of the outcomes and the fact that effects on exacerbations shown in early trials were larger than those reported by more recent studies. This may be a result of greater risk of selection or publication bias in earlier trials, thus benefits of treatment may not be as great as was suggested by previous evidence. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001287-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001287-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001287-abs-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001287-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001287-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001287-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001287-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001287-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001287-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001287-abs-0002" lang="en"> <h3>Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease</h3> <p><b>Background to the question</b> </p> <p>Chronic obstructive pulmonary disease (COPD) and chronic bronchitis are long‐term breathing conditions. They cause symptoms such as shortness of breath, cough, and excess sputum. People with COPD and chronic bronchitis may have flare‐ups (exacerbations) when their symptoms become worse. </p> <p>Mucolytics are medicines taken orally that may loosen sputum, making it easier to cough it up. Mucolytics may have other beneficial effects on lung infection and inflammation and may reduce the number of flare‐ups that people with COPD and chronic bronchitis have. Mucolytics can also be inhaled, but we did not look at inhaled mucolytics in this review. </p> <p><b>Study characteristics</b> </p> <p>We looked for studies lasting at least two months, in which it was decided at random whether a person received a mucolytic drug or a placebo. We did not include studies involving children or people with other breathing conditions such as asthma and cystic fibrosis. </p> <p>We found 38 studies to include in our review. These studies included a total of 10,377 adults with COPD or chronic bronchitis. The studies used a variety of mucolytic drugs, including N‐acetylcysteine, carbocysteine, and erdosteine and lasted from two months to three years. Mucolytics were taken by mouth between one and three times per day. These studies measured several different outcomes to find out if the drug was useful, including flare‐ups, hospital admissions, quality of life, lung function, and side effects. </p> <p><b>Key results</b> </p> <p>We found that people taking mucolytic drugs were less likely to experience a flare‐up compared to those taking placebo. Approximately eight people would need to take the drug for nine months for one extra person to avoid having a flare‐up. This result was based on 28 studies involving 6723 people. However, the studies carried out a longer time ago (1970s to 1990s) show greater benefit than those carried out more recently. Shorter studies also seemed to show more benefit than longer studies. This could be because the newer trials were larger and may be showing that mucolytics are less beneficial than the earlier studies showed. Or it could be that only studies that showed mucolytics as beneficial were published before the 2000s, when there was a push to report all trial results regardless of whether or not they showed benefit. </p> <p>People taking mucolytics had fewer days of disability (i.e. days when they could not do their normal activities) every month, but this was quite a small difference ‐ less than half a day per person per month. They were also approximately one‐third less likely to be admitted to hospital, although this result is based on only five studies that provided this information. </p> <p>Study results suggest that mucolytics do not have an important impact on quality of life or lung function. People taking mucolytics did not experience more unwanted side effects than those taking placebo. But we could not be sure about their impact on death during the study period because only 37 deaths occurred amongst the 3527 participants in studies where deaths were measured and reported. </p> <p><b>Quality of the evidence</b> </p> <p>We are moderately confident about the results we have presented. Our confidence is reduced by the results from individual studies looking quite different from one another and the mix of older and newer studies that we found. Also, in some cases there were not enough data to be sure whether mucolytics were better or worse than, or the same as, placebo. </p> <p><b>Conclusions</b> </p> <p>Mucolytics appear to be useful for reducing flare‐ups, days of disability, and hospital admissions in people with COPD or chronic bronchitis, and they do not appear to cause more side effects. However, they do not appear to have much impact on quality of life or lung function, and we could not be sure about their impact on death. </p> <p>This plain language summary is current to April 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001287-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001287-sec-0107"></div> <h3 class="title" id="CD001287-sec-0108">Implications for practice</h3> <section id="CD001287-sec-0108"> <p>Mucolytics may reduce the number of exacerbations in people with chronic bronchitis or chronic obstructive pulmonary disease (COPD) by a small quantity, and do not appear to be associated with an increase in adverse events. Approximately one person in eight may avoid having an exacerbation, provided all take treatment every day for an average of nine months. Mucolytics are associated with a reduction in days of disability per month and a reduction in hospitalisations in the studies that reported this outcome. Mucolytics have not been shown to substantially slow the decline in lung function, and it is uncertain whether they improve quality of life. Results are too imprecise to be certain whether or not there is an effect on mortality. As reduction in exacerbations seems the main potential benefit, mucolytics might be considered (1) a treatment option for patients with frequent exacerbations who cannot take other therapies such as inhaled corticosteroids or long‐acting bronchodilators, which have a stronger evidence base for their effectiveness; or (2) as add‐on treatment once all other therapies to reduce exacerbations have been utilised. </p> </section> <h3 class="title" id="CD001287-sec-0109">Implications for research</h3> <section id="CD001287-sec-0109"> <p>Future studies might address the value of mucolytic therapy:</p> <p> <ul id="CD001287-list-0008"> <li> <p>in patients who have multiple exacerbations per year, or who have prolonged or severe exacerbations; </p> </li> <li> <p>in patients already receiving current guideline‐based therapy; and</p> </li> <li> <p>in patients with repeated admissions to hospital with exacerbations of COPD despite maximal therapy to reduce acute exacerbations of COPD. </p> </li> </ul> </p> <p>Studies should stratify participants by (1) the new GOLD criteria (A‐D; <a href="./references#CD001287-bbs2-0069" title="Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. goldcopd.org/wp‐content/uploads/2018/11/GOLD‐2019‐v1.7‐FINAL‐14Nov2018‐WMS.pdf (accessed before 14 December 2018). ">GOLD 2019</a>), which incorporate symptoms and exacerbations, as well as spirometry; and (2) use of concomitant medications (such as inhaled corticosteroids (ICSs), long‐acting bronchodilators, or macrolide antibiotics). </p> <p>Outcomes of studies should include hospitalisations (COPD and all‐cause), mortality (COPD and all‐cause), numbers of days sick with exacerbations, and a validated measure of quality of life. A responder analysis for quality of life would add valuable information on the population effects of treatment. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001287-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001287-sec-0029"></div> <div class="table" id="CD001287-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Mucolytic compared to placebo for chronic bronchitis or chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mucolytic compared to placebo for chronic bronchitis or chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> chronic bronchitis or COPD<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> mucolytic<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes*</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects† (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mucolytic</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with no exacerbations in study period</b> </p> <p>Follow‐up: 8.8 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>386 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>521 per 1000<br/> (495 to 545) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 1.73<br/> (1.56 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6723<br/> (28 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generally larger effects in earlier studies of mucolytics in chronic bronchitis and smaller effects in more recent studies in COPD </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days of disability per participant per month</b> </p> <p>Follow‐up: 8.3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of disability per participant per month was 1.57 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.43 days lower<br/> (0.56 lower to 0.30 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2259<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life (total score SGRQ)</b> </p> <p>Scale from 1 to 100; lower scores indicate better quality of life</p> <p>Follow‐up: 14.1 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ total score was 39.02 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.37 lower<br/> (2.85 lower to 0.11 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2721<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID for SGRQ is 4 points</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation during study period</b> </p> <p>Follow‐up: 16.6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000<br/> (107 to 171) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.68<br/> (0.52 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1833<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV</b> ₁<b>at end of study</b> </p> <p>Follow‐up: 14.5 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean FEV₁ at end of study was 1.50 L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.04 L higher<br/> (0.01 higher to 0.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3473<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID for FEV₁ in COPD is approximately 0.1 L (<a href="./references#CD001287-bbs2-0076" title="JonesPW , BeehKM , ChapmanKR , DecramerM , MahlerDA , WedzichaJA . Minimal clinically important differences in pharmacological trials. American Journal of Respiratory and Critical Care Medicine2013;189(3):250‐5. ">Jones 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: 8.2 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>235 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000<br/> (185 to 224) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.84<br/> (0.74 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7264<br/> (24 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death during study period</b> </p> <p>Follow‐up: 13.3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (5 to 20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.98<br/> (0.51 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3527<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 deaths on mucolytics and 19 on placebo</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Follow‐up was calculated as a weighted mean duration.<br/> †<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>CI: confidence interval; COPD: chronic obstructive pulmonary disease; FEV₁: forced expiratory volume in one second; MCID: minimally clinically important difference; MD: mean difference; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio; SGRQ: St. George's Respiartory Questionaire; WMD: weighted mean duration. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Statistical and clinical heterogeneity identified. Downgraded once for inconsistency. </p> <p><sup>b</sup>Funnel plots suggest small negative trials under‐represented (<a href="./full#CD001287-fig-0001">Figure 1</a>; <a href="./full#CD001287-fig-0002">Figure 2</a>). However, removing the positive small trials from the analysis had little impact on the pooled estimate. No downgrade. </p> <p><sup>c</sup>Confidence interval includes possibility of no difference between groups, but both ends of confidence interval lie within MCID. No downgrade for imprecision. </p> <p><sup>d</sup>Confidence interval includes possibility of both an important increase or reduction in deaths. Downgraded once for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD001287-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.11 Days of disability per participant per month." data-id="CD001287-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.11 Days of disability per participant per month. </p> </div> </div> </div> <div class="figure" id="CD001287-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.13 FEV₁ at end of study." data-id="CD001287-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.13 FEV₁ at end of study. </p> </div> </div> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001287-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001287-sec-0030"></div> <section id="CD001287-sec-0031"> <h3 class="title" id="CD001287-sec-0031">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is a long‐term progressive condition primarily affecting the lungs, but with a wide range of extrapulmonary manifestations. Symptoms typically include shortness of breath (dyspnoea), impaired exercise tolerance, wheezing, cough, and sputum production. In more severe cases, COPD may progress to cor pulmonale, respiratory failure, and death (<a href="./references#CD001287-bbs2-0080" title="QaseemA , WiltTJ , WeinbergerSE , HananiaNA , CrinerG , van derMolenT , et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine2011;155(3):179‐91. ">Qaseem 2011</a>). It is estimated that COPD is the fourth most common single cause of death worldwide (<a href="./references#CD001287-bbs2-0088" title="World Health Organization. The top 10 causes of death. www.who.int/mediacentre/factsheets/fs310/en/ (accessed before 14 December 2018). ">WHO 2017</a>). Few interventions have been demonstrated to convincingly reduce mortality, with the exception of smoking cessation, long‐term oxygen therapy in hypoxaemic patients and lung volume reduction surgery in selected patients (<a href="./references#CD001287-bbs2-0069" title="Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. goldcopd.org/wp‐content/uploads/2018/11/GOLD‐2019‐v1.7‐FINAL‐14Nov2018‐WMS.pdf (accessed before 14 December 2018). ">GOLD 2019</a>; <a href="./references#CD001287-bbs2-0086" title="vanAgterenJEM , CarsonKV , TiongLU , SmithBJ . Lung volume reduction surgery for diffuse emphysema. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD001001.pub3] ">van Agteren 2016</a>). </p> <p>A diagnosis of COPD is usually made when a person who has symptoms of COPD is found to have airflow obstruction (post‐bronchodilator forced expiratory volume in one second (FEV₁)/forced vital capacity (FVC) &lt; 0.70) in the absence of an alternative explanation for the symptoms (e.g. left ventricular failure) or the airflow obstruction (e.g. asthma) (<a href="./references#CD001287-bbs2-0080" title="QaseemA , WiltTJ , WeinbergerSE , HananiaNA , CrinerG , van derMolenT , et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine2011;155(3):179‐91. ">Qaseem 2011</a>). Many people with chronic bronchitis also have COPD. Smoking is the main risk factor for COPD; up to 50% of smokers will develop COPD, and most will have some breathing impairment (<a href="./references#CD001287-bbs2-0069" title="Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. goldcopd.org/wp‐content/uploads/2018/11/GOLD‐2019‐v1.7‐FINAL‐14Nov2018‐WMS.pdf (accessed before 14 December 2018). ">GOLD 2019</a>; <a href="./references#CD001287-bbs2-0082" title="RennardSI , VestboJ . COPD: the dangerous underestimate of 15%. Lancet2006;367(9518):1216‐9. ">Rennard 2006</a>). Chronic bronchitis and COPD are preventable and treatable diseases that are associated with an enhanced chronic inflammatory response to noxious particles or gases in the airways and the lung (<a href="./references#CD001287-bbs2-0069" title="Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. goldcopd.org/wp‐content/uploads/2018/11/GOLD‐2019‐v1.7‐FINAL‐14Nov2018‐WMS.pdf (accessed before 14 December 2018). ">GOLD 2019</a>). Exacerbations and comorbidities contribute to overall severity in individual patients. </p> <p>Exacerbations occur with increasing frequency as the disease becomes more severe. They are characterised by increased breathlessness or greater volume or purulence of sputum, or both. Exacerbations accelerate decline in lung function and are associated with worse quality of life and higher mortality. They are the largest contributor to healthcare costs in COPD (<a href="./references#CD001287-bbs2-0067" title="CrinerGJ , BourbeauJ , DiekemperRL , OuelletteDR , GoodridgeD , HernandezP , et al. Prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest2015;147(4):883‐93. ">Criner 2015</a>). Thus, treatments that reduce the frequency and duration of acute exacerbations will provide benefit for both individual patients and healthcare systems. </p> </section> <section id="CD001287-sec-0032"> <h3 class="title" id="CD001287-sec-0032">Description of the intervention</h3> <p>Mucolytics are oral medicines, given at least once daily, that are believed to increase expectoration of sputum by reducing its viscosity, thus making it easier to cough it up. There are several different types of mucolytic, including carbocysteine, acetylcysteine, erdosteine, and ambroxol (<a href="./references#CD001287-bbs2-0089" title="YangIA , BrownJL , GeorgeJ , JenkinsS , McDonaldCF , McDonaldV , et al. The COPD‐X Plan: Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease. Version 2.53. copdx.org.au/wp‐content/uploads/2018/11/COPDX‐V2‐55‐Aug‐2018.pdf (accessed before 13 December 2018). ">Yang 2018</a>). They are given in combination with, rather than instead of, other COPD therapies, such as inhaled long‐acting beta₂‐agonists (LABAs) and long‐acting muscarinic antagonists (LAMAs). </p> <p>Mucolytics are included as a treatment option for patients experiencing frequent exacerbations in several national and international management guidelines. International Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines state that mucolytics may reduce exacerbations and modestly improve health status, but there is currently a lack of evidence to precisely target the population most likely to benefit (<a href="./references#CD001287-bbs2-0069" title="Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. goldcopd.org/wp‐content/uploads/2018/11/GOLD‐2019‐v1.7‐FINAL‐14Nov2018‐WMS.pdf (accessed before 14 December 2018). ">GOLD 2019</a>). COPD‐X guidelines, produced in Australia and New Zealand, give a stronger recommendation, stating "there is evidence to support the use of high dose oral N‐acetylcysteine in the reduction of COPD exacerbations and improvements in lung function" and "high dose (≥ 1200 mg/day) N‐acetylcysteine should be considered as an effective therapy for reducing exacerbations" (<a href="./references#CD001287-bbs2-0089" title="YangIA , BrownJL , GeorgeJ , JenkinsS , McDonaldCF , McDonaldV , et al. The COPD‐X Plan: Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease. Version 2.53. copdx.org.au/wp‐content/uploads/2018/11/COPDX‐V2‐55‐Aug‐2018.pdf (accessed before 13 December 2018). ">Yang 2018</a>). UK National Institute for Health and Care Excellence (NICE) guidelines currently suggest that mucolytics should be considered for patients with chronic cough productive of sputum and continued if there is symptomatic improvement. However, the guidelines state they should not be routinely prescribed to prevent exacerbations (<a href="./references#CD001287-bbs2-0079" title="National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. www.nice.org.uk/guidance/ng115 (accessed before 14 December 2018). ">NICE 2018</a>). Joint American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for prevention of exacerbations make the following recommendation: "for patients who have COPD with moderate or severe airflow obstruction and exacerbations despite optimal inhaled therapy, we suggest treatment with an oral mucolytic agent to prevent future exacerbations" (<a href="./references#CD001287-bbs2-0087" title="WedzichaJA , CalverleyPMA , AlbertRK , AnzuetoA , CrinerGJ , HurstJR , et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal2017;50(3):pii: 1602265. ">Wedzicha 2017</a>). However, this is qualified as being a conditional recommendation, based on low quality of evidence. </p> </section> <section id="CD001287-sec-0033"> <h3 class="title" id="CD001287-sec-0033">How the intervention might work</h3> <p>Mucus clearance is one of the most important tools the lung has to protect itself from pathogens (<a href="./references#CD001287-bbs2-0084" title="RubinBK . Secretion properties, clearance, and therapy in airway disease. Translational Respiratory Medicine2014;2:6. ">Rubin 2014</a>). Mucus is a gel‐like material complete with glycoproteins called mucins, serum proteins, and water. In contrast, sputum refers to expectorated mucus with the addition of inflammatory cells and DNA. Mucus is removed from the lungs and airways via cilia hairs and airflow; however sputum is removed primarily by coughing (<a href="./references#CD001287-bbs2-0084" title="RubinBK . Secretion properties, clearance, and therapy in airway disease. Translational Respiratory Medicine2014;2:6. ">Rubin 2014</a>). </p> <p>Mucolytics work by changing the physical properties of the secretions themselves. They can work by degrading the mucin polymers, fibrin, or DNA in airway secretions, which makes them less viscous. This makes it easier for the body to clear them and reduces the risk of bacterial contamination. Classic mucolytics such as N‐acetylcysteine (NAC) exert their effects by depolymerising the mucin glycoproteins via a hydrolysis reaction (<a href="./references#CD001287-bbs2-0083" title="RubinBK . Mucolytics, expectorants, and mucokinetic medications. Respiratory Care2007;52:859–65. ">Rubin 2007</a>). One study found that NAC may improve pulmonary function, but there was uncertainty as to whether or not this was in fact mediated by its antioxidant ability (<a href="./references#CD001287-bbs2-0018" title="HansenNC , SkriverA , Brorsen‐RiisL , BalsløvS , EvaldT , MaltbaekN , et al. Orally administered N‐acetylcysteine may improve general well‐being in patients with mild chronic bronchitis. Respiratory Medicine1994;88:531‐5. ">Hansen 1994</a>). Given that oxidative stress is thought to be an amplifying mechanism in COPD (<a href="./references#CD001287-bbs2-0081" title="RahmanI . Oxidative stress in the pathogenesis of chronic obstructive pulmonary disease; cellular and molecular mechanisms. Cell Biochemistry and Biophysics2005;43(1):167‐88. ">Rahman 2005</a>), this property of N‐acetylcysteine may be useful in chronic airways disease. </p> <p>Lubricants and surfactant stimulators such as ambroxol can make the sputum less adhesive, making it easier for the cilia to clear and more likely that a cough will be able to transport it throughout the pharynx (<a href="./references#CD001287-bbs2-0083" title="RubinBK . Mucolytics, expectorants, and mucokinetic medications. Respiratory Care2007;52:859–65. ">Rubin 2007</a>). In a chronic inflammatory process such as COPD, production of phospholipase A2 can cause destruction of the surfactant phospholipids, making the sputum incredibly adherent to the cilia and further causing airway obstruction (<a href="./references#CD001287-bbs2-0083" title="RubinBK . Mucolytics, expectorants, and mucokinetic medications. Respiratory Care2007;52:859–65. ">Rubin 2007</a>). One study found that aerosolised surfactant was able to increase FEV₁ % predicted and FVC by up to 10% by reducing adherence of mucus in the airways (<a href="./references#CD001287-bbs2-0062" title="AnzuetoA , JubranA , OharJA , PiquetteCA , RennardSI , ColiceG . Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. Journal of American Medical Association1997;278(17):1426–31. ">Anzueto 1997</a>). </p> </section> <section id="CD001287-sec-0034"> <h3 class="title" id="CD001287-sec-0034">Why it is important to do this review</h3> <p>As illustrated by varied recommendations from guidelines, there is lack of international consensus on the place of mucolytics in the treatment of COPD. As theoretical reasons have been proposed to explain why mucolytics may work in both chronic bronchitis and COPD, and because treatments that reduce exacerbations are needed to reduce morbidity and costs, this review update will seek to determine the true effect of this class of medicines. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001287-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001287-sec-0035"></div> <section id="CD001287-sec-0036"> <h3 class="title" id="CD001287-sec-0036">Primary objective</h3> <p> <ul id="CD001287-list-0001"> <li> <p>To determine whether treatment with mucolytics reduces exacerbations and/or days of disability in patients with chronic bronchitis or COPD </p> </li> </ul> </p> </section> <section id="CD001287-sec-0037"> <h3 class="title" id="CD001287-sec-0037">Secondary objectives</h3> <p> <ul id="CD001287-list-0002"> <li> <p>To assess whether mucolytics lead to improvement in lung function or quality of life</p> </li> <li> <p>To determine the frequency of adverse effects associated with use of mucolytics</p> </li> </ul> </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001287-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001287-sec-0038"></div> <section id="CD001287-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001287-sec-0040"> <h4 class="title">Types of studies</h4> <p>We included randomised, placebo‐controlled trials.</p> </section> <section id="CD001287-sec-0041"> <h4 class="title">Types of participants</h4> <p>We included studies of adults (over 20 years of age) with chronic bronchitis as defined by the British Medical Research Council (cough and sputum on most days during at least three consecutive months for longer than two successive years) or COPD as defined by the criteria of the American Thoracic Society, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), the European Respiratory Society, or the World Health Organization (WHO). We excluded studies on patients with asthma or cystic fibrosis. </p> </section> <section id="CD001287-sec-0042"> <h4 class="title">Types of interventions</h4> <p>Participants must have received regular treatment with oral mucolytics or placebo for at least two months. Oral mucolytics included the following compounds: N‐acetylcysteine (NAC), S‐carboxymethylcysteine, bromhexine, ambroxol, erdosteine, sobrerol, cithiolone, letosteine, iodinated glycerol, N‐isobutyrylcysteine, myrtol, and cineole. </p> <p>We excluded studies of inhaled mucolytics and combinations of mucolytics with antibiotics and mucolytics with bronchodilators, as well as studies of deoxyribonuclease or proteases such as trypsin. </p> </section> <section id="CD001287-sec-0043"> <h4 class="title">Types of outcome measures</h4> <section id="CD001287-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD001287-list-0003"> <li> <p>Exacerbations, as measured by the number of participants with no exacerbations during the study period, as well as the total number of acute exacerbations per participant* and time to first exacerbation. Exacerbation was defined as an increase in cough and by volume and/or purulence of sputum </p> </li> <li> <p>Number of days of disability variously defined as days in bed, days off work, or days on which the participant was unable to undertake normal activities. We also assessed days on antibiotics </p> </li> </ul> </p> <p>*For the 2019 update, we removed exacerbations per patient per month analyses as these are not considered to be as statistically robust as the dichotomous exacerbation outcome, largely due to likely skew in this measure. Instead we present these data in tables. </p> </section> <section id="CD001287-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD001287-list-0004"> <li> <p>Measures of lung function, including forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), and peak expiratory flow rate (PEFR) </p> </li> <li> <p>Adverse effects of treatment</p> </li> <li> <p>Hospitalisation and mortality</p> </li> <li> <p>Quality of life as measured by a tool validated in patients with COPD</p> </li> </ul> </p> <p>We had intended to use symptom scores as a secondary outcome measure, but it became clear that symptoms were not reported in a consistent fashion, and it was not possible to standardise symptom scores. </p> <p>Adverse events were not usually reported in detail and generally were mild and self‐limiting, so we have entered only the total number of adverse events. </p> </section> </section> </section> <section id="CD001287-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001287-sec-0047"> <h4 class="title">Electronic searches</h4> <p>Search methods and search history for previous versions of this review are detailed in <a href="./appendices#CD001287-sec-0113">Appendix 1</a>. The previously published version included searches up to July 2014. The search period for this update is July 2014 through April 2019. </p> <p>We identified studies from the Cochrane Airways Group Trials Register (CAGR), which is maintained by the Information Specialist for the Group. The Cochrane Airways Trials Register contains studies identified from several sources. </p> <p> <ul id="CD001287-list-0005"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies (CRS). </p> </li> <li> <p>Weekly searches of MEDLINE Ovid.</p> </li> <li> <p>Weekly searches of Embase Ovid.</p> </li> <li> <p>Monthly searches of PsycINFO Ovid.</p> </li> <li> <p>Monthly searches of Cumulative Index to Nursing and Allied Health Literature (CINAHL) EBSCO. </p> </li> <li> <p>Handsearches of the proceedings of major respiratory conferences.</p> </li> </ul> </p> <p>Studies contained in the Trials Register are identified through search strategies based on the scope of Cochrane Airways. Details of these strategies, as well as a list of handsearched conference proceedings, are provided in <a href="./appendices#CD001287-sec-0114">Appendix 2</a>. We searched for relevant trials in the Register using the search strategy presented in <a href="./appendices#CD001287-sec-0120">Appendix 3</a>. We did not apply restrictions on language or type of publication. </p> </section> <section id="CD001287-sec-0048"> <h4 class="title">Searching other resources</h4> <p>We checked the references of all papers and reviews for which we obtained the full text to identify other relevant articles. We asked other researchers in the field to provide additional references, and we remained open to unsolicited suggestions regarding potentially eligible studies. For the 2014 and 2019 updates, we searched these online clinical trials registers: ClinicalTrials.gov (www.ClinicalTrials.gov) and the WHO trials portal (www.who.int/ictrp/en/). </p> </section> </section> <section id="CD001287-sec-0049"> <h3 class="title" id="CD001287-sec-0049">Data collection and analysis</h3> <section id="CD001287-sec-0050"> <h4 class="title">Selection of studies</h4> <p>At least one review author (Peter Black and PP for original review; PP and Jimmy Chong for the 2001, 2006, and 2012 updates; and PP and RF for the 2019 update) assessed all abstracts obtained from the search of the CAGR. We obtained the full text for those that appeared to fit the criteria for inclusion (or if this was not clear from the abstract). Two review authors independently selected trials for inclusion in the original review and updates and resolved disagreements over inclusion by discussion. Six translators (two of whom were medically trained) assessed papers published in languages other than English. For the 2012 and 2014 updates, the review lead author (PP) was assisted by another Cochrane review author (Jimmy Chong) in extracting data. For the 2019 update, RF and KS extracted and entered data, with input from PP. </p> </section> <section id="CD001287-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>We extracted data onto worksheets before entering them into the Review Manager software (RevMan 5.3). We double‐checked all entries against the original paper. In the 1999 update, we rechecked all data from earlier studies. In the 2019 update, we rechecked lung function data from earlier studies to separate the analyses into FEV₁, percent predicted FEV₁, PEFR, and FVC, rather than a combined standardised mean difference analysis. </p> </section> <section id="CD001287-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the following to assess sources of bias in selection, allocation, performance, detection, attrition, or reporting (<a href="./references#CD001287-bbs2-0073" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration,2011. [Available from www.handbook.cochrane.org] ">Higgins 2011</a>). </p> <p> <ul id="CD001287-list-0006"> <li> <p>Low risk of bias.</p> </li> <li> <p>Unclear risk of bias: if insufficient information was available.</p> </li> <li> <p>High risk of bias.</p> </li> </ul> </p> <p>When assessing attrition bias, we used an approximate cut‐off of 20% dropout for high risk, although we also took into account the type of analysis performed (e.g. intention‐to‐treat), the balance between trial arms, and the reasons given for dropout. </p> </section> <section id="CD001287-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed continuous data using mean differences (MDs). We used Peto odds ratios (ORs) for dichotomous data and reported results with 95% confidence intervals (CIs). </p> </section> <section id="CD001287-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>We calculated exacerbation rates and days of disability by dividing the number of events by the number of participants and the number of months of the study (i.e. per participant per month). We scaled standard deviations for monthly rates in the same way. For the 2019 update, we archived the exacerbation rates analyses. </p> </section> <section id="CD001287-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>If data were insufficient, we requested further information by writing to the study author or to the pharmaceutical company sponsoring the study. </p> </section> <section id="CD001287-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity among the trials in each analysis. We reported cases of substantial heterogeneity and explored possible causes by performing prespecified subgroup analysis. As per the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001287-bbs2-0073" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration,2011. [Available from www.handbook.cochrane.org] ">Higgins 2011</a>), we considered the following ranges for assessing heterogeneity. </p> <p> <ul id="CD001287-list-0007"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: may show considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD001287-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>When we were able to pool more than 10 trials, we created and examined a funnel plot to explore possible small‐study and publication biases. </p> </section> <section id="CD001287-sec-0058"> <h4 class="title">Data synthesis</h4> <p>We used summary statistics rather than individual patient data. We used a fixed‐effect model. </p> <p>For the outcome of having 'no exacerbation in the study period', we calculated a number needed to treat for an additional beneficial outcome (NNTB) based on the pooled Peto odds ratio (<a href="./references#CD001287-bbs2-0064" title="CatesCJ . Simpson's paradox and calculation of number needed to treat from meta‐analysis. BMC Medical Research Methodology2002;2:1. [DOI: 10.1186/1471‐2288‐2‐1] ">Cates 2002</a>), with baseline risk taken from the pooled control group event rate (total number of events divided by overall number of participants in the placebo group multiplied by 100). </p> </section> <section id="CD001287-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>From the outset, we planned a priori subgroup analyses based on type of mucolytic, dose, duration, country of study, disease severity, and whether or not participants were included, as they had a history of exacerbation. </p> <p>Following publication of the BRONCUS study (<a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a>), which suggested a differential effect of mucolytics depending on concomitant treatment, we included an analysis on whether concomitant inhaled corticosteroids were permitted. </p> <p>From 2012 onwards, we carried out a post hoc investigation of time trends in data for participants with one or more exacerbations by comparing results of trials published since 2000 versus those published earlier. </p> </section> <section id="CD001287-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>For 2012 onwards, we explored heterogeneity in results on exacerbations, and we conducted a sensitivity analysis using data from trials assessed as having low risk of selection bias (on the basis of allocation concealment). For the 2019 update, we conducted a sensitivity analysis removing studies judged to be at high risk of attrition bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001287-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001287-sec-0061"></div> <section id="CD001287-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD001287-sec-0063"> <h4 class="title">Results of the search</h4> <p>For details of the search history, see <a href="./appendices#CD001287-sec-0113">Appendix 1</a>, and for the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) study flow diagram for this update, see <a href="#CD001287-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001287-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram: review update." data-id="CD001287-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> </div> <p>After de‐duplication, the database search run on 23 April 2019 yielded 98 references, and searches of clinical trial registries identified a further 18 records. We excluded 93 on the basis of title and abstract and reviewed 23 full texts for possible inclusion. We excluded a further six records (five unique studies) at this stage and identified two ongoing studies that meet the inclusion criteria for this review (<a href="./references#CD001287-sec-0140" title="">Characteristics of ongoing studies</a>). The remaining 15 records were eligible for inclusion. We added nine records, linked to four new unique studies, to the review (<a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a>; <a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a>; <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>; <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a>). We identified a further six records, which were additional references to studies already included in the review. We wrote to authors of all four newly included studies to request further information; we received a response from the authors of <a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a>, <a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a>, and <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>, and we are grateful to Professor Dal Negro, Professor Inoue, and Dr Niewoehner for the additional data/details they provided. </p> <p>The 2014 search yielded 29 abstracts, as well as four new eligible studies ‐ all of NAC versus placebo. Four abstracts related to the eligible study of <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>, four to <a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a>, three to <a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a>, and one to <a href="./references#CD001287-bbs2-0032" title="RoyP , HaranA , SrinivasBN . Role of n‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication2013;45:S107. RoyP , HaranA , SrinivasBN , MjumdarP . Evaluation of effect of N‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences2014;3(1):95‐105. ">Roy 2014</a>. We found a total of 17 reports of ineligible studies, including <a href="./references#CD001287-bbs2-0048" title="MorettiM , BallabioM . Effect of erdosteine on airflow obstruction and symptom recovery in severe COPD exacerbations [Abstract]. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):76s [P536]. ">Moretti 2011</a>, which in 2012 was awaiting classification. We found a further report of the Roy study while searching for study authors' contact details. Searches of online clinical trials databases yielded no further studies. </p> <p>In the initial review in 1997, we wrote to the authors of 10 studies (<a href="./references#CD001287-bbs2-0001" title="AllegraL , CordaroCI , GrassiC . Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double‐blind, placebo‐controlled trial. Respiration1996;63:174‐80. ">Allegra 1996</a>; <a href="./references#CD001287-bbs2-0002" title="Multicenter Study Group. Long‐term oral acetylcysteine in chronic bronchitis. A double‐blind controlled study. European Journal of Respiratory Disease1980;61(111 Suppl):93‐108. ">Babolini 1980</a>; <a href="./references#CD001287-bbs2-0004" title="BomanG , BackerU , LarssonS , MelanderB , WahlanderL . Oral acetylcysteine reduces exacerbation rate in chronic bronchitis; report of a trial organized by the Swedish Society for Pulmonary Diseases. European Journal of Respiratory Disease1983;64:405‐15. ">Boman 1983</a>; <a href="./references#CD001287-bbs2-0007" title="CastiglioniCL , GramoliniC . Effect of long‐term treatment with sobrerol on the exacerbations of chronic bronchitis. Respiration1986;50:202‐17. ">Castiglioni 1986</a>; <a href="./references#CD001287-bbs2-0041" title="AndreasenT . Mucolytic treatment of chronic bronchitis during two winter periods. Scandinavian Journal of Respiratory Disease1974;90:69‐70. ChristensenSB , KjerJ , RyskjaerS , Arseth‐HansenP , ChristensenF . Mucolytic treatment of chronic bronchitis during two winter periods. Scandinavian Journal of Respiratory Disease1971;52(1):48‐57. ">Christensen 1971</a>; <a href="./references#CD001287-bbs2-0017" title="GrillageM , Barnard‐JonesK . Long‐term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. British Journal of Clinical Practice1985;39(10):395‐8. ">Grillage 1985</a>; <a href="./references#CD001287-bbs2-0019" title="JacksonIM , BarnesJ , CookseyP . Efficacy and tolerability of oral acetylcysteine (fabrol) in chronic bronchitis: a double‐blind placebo controlled trial. Journal of International Medical Research1984;12:198‐206. ">Jackson 1984</a>; <a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a>; <a href="./references#CD001287-bbs2-0028" title="ParrGD , HuitsonA . Oral fabrol (oral n‐acetyl‐cysteine) in chronic bronchitis. British Journal of Diseases of the Chest1987;81(4):341‐8. ">Parr 1987</a>; <a href="./references#CD001287-bbs2-0030" title="MorganEJ , PettyTL . Summary of the national mucolytic study. Chest1990;97(Suppl):24S‐7S. PettyTL . The national mucolytic study: results of a randomized, double‐blind, placebo‐controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest1990;97(1):75‐83. ">Petty 1990</a>) to request more information. We received further data for two studies (<a href="./references#CD001287-bbs2-0001" title="AllegraL , CordaroCI , GrassiC . Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double‐blind, placebo‐controlled trial. Respiration1996;63:174‐80. ">Allegra 1996</a>; <a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a>). Dr Petty responded to our letter but could not supply data because they were held by a pharmaceutical company (the company has not replied to two letters). Dr Boman wrote to say that he was unable to supply us with additional data. This was also the case for Novartis Pharmaceuticals (UK), which responded on behalf of two study authors (<a href="./references#CD001287-bbs2-0019" title="JacksonIM , BarnesJ , CookseyP . Efficacy and tolerability of oral acetylcysteine (fabrol) in chronic bronchitis: a double‐blind placebo controlled trial. Journal of International Medical Research1984;12:198‐206. ">Jackson 1984</a>; <a href="./references#CD001287-bbs2-0028" title="ParrGD , HuitsonA . Oral fabrol (oral n‐acetyl‐cysteine) in chronic bronchitis. British Journal of Diseases of the Chest1987;81(4):341‐8. ">Parr 1987</a>), and Parke Davis Research Laboratories (<a href="./references#CD001287-bbs2-0017" title="GrillageM , Barnard‐JonesK . Long‐term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. British Journal of Clinical Practice1985;39(10):395‐8. ">Grillage 1985</a>). We received no reply to our request for additional data related to the remaining three studies (<a href="./references#CD001287-bbs2-0002" title="Multicenter Study Group. Long‐term oral acetylcysteine in chronic bronchitis. A double‐blind controlled study. European Journal of Respiratory Disease1980;61(111 Suppl):93‐108. ">Babolini 1980</a>; <a href="./references#CD001287-bbs2-0007" title="CastiglioniCL , GramoliniC . Effect of long‐term treatment with sobrerol on the exacerbations of chronic bronchitis. Respiration1986;50:202‐17. ">Castiglioni 1986</a>; <a href="./references#CD001287-bbs2-0041" title="AndreasenT . Mucolytic treatment of chronic bronchitis during two winter periods. Scandinavian Journal of Respiratory Disease1974;90:69‐70. ChristensenSB , KjerJ , RyskjaerS , Arseth‐HansenP , ChristensenF . Mucolytic treatment of chronic bronchitis during two winter periods. Scandinavian Journal of Respiratory Disease1971;52(1):48‐57. ">Christensen 1971</a>), although we sent two letters. We also wrote to the authors of <a href="./references#CD001287-bbs2-0027" title="OlivieriD , ZavattiniG , TomasiniG , DaniottiS , BonsignoreG , FerraraG , et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long‐term multicenter trial. Respiration1987;51 Suppl 1:42‐51. ">Olivieri 1987</a> to clarify the error measurement used, but we received no reply. Pharmaceutical companies notified us of two studies (<a href="./references#CD001287-bbs2-0023" title="MeisterR . Long‐term therapy with acetylcysteine retard tablets in patients with chronic bronchitis: a double‐blind, placebo controlled study. Unpublished source1986. ">Meister 1986</a>; <a href="./references#CD001287-bbs2-0024" title="BeehK‐M , BeierJ , CandlerH , WittigT . Effect of ELOM‐080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype ‐ a post‐hoc analysis of a randomized, double‐blind, placebo‐controlled clinical trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2877‐84. MeisterR , WittigT , BeuscherN , deMeyC . Efficacy and tolerability of myrtol standardized in long‐term treatment of chronic bronchitis. A double‐blind, placebo‐controlled study. Study Group Investigators. Arzneimittelforschung1999;49(4):351‐8. ">Meister 1999</a>); the former was unpublished. They also provided further information on four studies (<a href="./references#CD001287-bbs2-0023" title="MeisterR . Long‐term therapy with acetylcysteine retard tablets in patients with chronic bronchitis: a double‐blind, placebo controlled study. Unpublished source1986. ">Meister 1986</a>; <a href="./references#CD001287-bbs2-0024" title="BeehK‐M , BeierJ , CandlerH , WittigT . Effect of ELOM‐080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype ‐ a post‐hoc analysis of a randomized, double‐blind, placebo‐controlled clinical trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2877‐84. MeisterR , WittigT , BeuscherN , deMeyC . Efficacy and tolerability of myrtol standardized in long‐term treatment of chronic bronchitis. A double‐blind, placebo‐controlled study. Study Group Investigators. Arzneimittelforschung1999;49(4):351‐8. ">Meister 1999</a>; <a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a>; <a href="./references#CD001287-bbs2-0029" title="PelaR , CalcagniAM , SubiacoS , IsidoriP , TubaldiA , SanguinettiCM . N‐acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration1999;66(6):495‐500. ">Pela 1999</a>). In 2008 we contacted an author of the COOPT study, 'A double‐blind placebo‐controlled trial comparing the efficacy and cost‐effectiveness of inhaled fluticasone propionate versus oral N‐acetylcysteine in the treatment of patients with COPD in general practice' (Clinical Trials identifier: NCT00184977), which was conducted from 1998 to 2003, to ascertain whether any data might be made available for this review. This study has now been published and is included in the review (<a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a>). In 2012, we contacted the lead author of <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a> to clarify conflicting information on quality of life in the published report; the lead author helpfully provided us with information derived from the St George's Respiratory Questionnaire (SGRQ). </p> <p>In 2014, we wrote to Dr De Backer to request additional details on the secondary outcomes of spirometry and quality of life (<a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a>), but we received no response. As this was a small cross‐over study with few outcomes of relevance to this review, we have not pursued this. Dr Zheng provided the appendix to <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>, which contained further details on study design and outcomes. In response to another request, Dr Zheng provided standard deviations (SDs) of exacerbation rates and total SGRQ, as well as mean (SD) end of study FEV₁ and FVC values. </p> </section> <section id="CD001287-sec-0064"> <h4 class="title">Included studies</h4> <p>By 2019, this review included 38 randomised controlled trials (RCTs), which had recruited a total of 10,377 participants. We provide full details of each study in <a href="./references#CD001287-sec-0137" title="">Characteristics of included studies</a> and an overview in <a href="#CD001287-tbl-0002">Table 1</a>. </p> <div class="table" id="CD001287-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study<br/> duration<br/> (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean<br/> age<br/> (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>COPD<br/> severity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0001" title="AllegraL , CordaroCI , GrassiC . Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double‐blind, placebo‐controlled trial. Respiration1996;63:174‐80. ">Allegra 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbocysteine‐lysine 2.7 g daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diary of scores, exacerbations, time to first exacerbation, duration of exacerbation, days on antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0002" title="Multicenter Study Group. Long‐term oral acetylcysteine in chronic bronchitis. A double‐blind controlled study. European Journal of Respiratory Disease1980;61(111 Suppl):93‐108. ">Babolini 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, symptom scores, global assessments by patients and physicians, AEs, days on antibiotics </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0003" title="BachhAA , ShahNN , BhargavaR , AhmadZ , PandeyDK , DarKA . Effect of oral N‐acetylcysteine in COPD ‐ a randomised controlled trial. JK‐Practitioner2007;14(1):12‐6. ">Bachh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, hospital admissions, lung function, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0004" title="BomanG , BackerU , LarssonS , MelanderB , WahlanderL . Oral acetylcysteine reduces exacerbation rate in chronic bronchitis; report of a trial organized by the Swedish Society for Pulmonary Diseases. European Journal of Respiratory Disease1983;64:405‐15. ">Boman 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe<br/> to very<br/> severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, sick leave due to exacerbation, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0005" title="BontognaliE . Clinical effectiveness and tolerance of cithiolone in the prophylaxis of acute infective exacerbations in patients suffering from chronic bronchitis. Acta Therapeutica1991;17:155‐62. ">Bontognali 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cithiolone 400 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo for 1 month followed by 400 mg once daily for a further 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, duration of acute exacerbations, FEV₁, FVC, sputum viscosity, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0006" title="BorgiaM , SepeN , Ori‐BelomettiM , BorgiaR . Comparison between acetylcysteine and placebo in the long term treatment of chronic bronchitis [Confronto tra acetilcisteina e placebo nel trattamento a lungo termine della bronchite cronica]. Gazzetta Medica Italiana1981;140:467‐72. ">Borgia 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, lung function, symptom scores, clinical assessments, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0007" title="CastiglioniCL , GramoliniC . Effect of long‐term treatment with sobrerol on the exacerbations of chronic bronchitis. Respiration1986;50:202‐17. ">Castiglioni 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sobrerol 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation rate, consumption of antibiotics, clinical signs, laboratory data, lung function, global assessment by investigator and patient, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0008" title="CeglaUH . Long‐term treatment of chronic bronchitis for two years with ambroxol (Mucosolvan) retard capsules. Results of a double blind trial including 180 patients [Langzeittherapie uber 2 Jahre mit Ambroxol (Mucosolvan) Retardkapseln bei Patienten mit chronischer Bronchitis. Ergebnisse einer Doppelblindstudie an 180 Patienten]. Praxis Klinik der Pneumologie1988;42:715‐21. ">Cegla 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ambroxol retard 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, days sick (off work, in hospital), patient symptoms by diary card, lung function, extra medication use, assessment by investigator and patient, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0009" title="CremoniniC , SpadaE , CelliniF , CioniR , GiovanniniM , PerriG , et al. I farmaci attivi sul muco nel trattamento di fondo della bronchite cronica [Pharmacotherapy which acts on mucus in long‐term treatment of chronic bronchitis]. La Clinica Terapeutica1986;116:121‐9. ">Cremonini 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Letosteine 50 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, days off sick, lung function</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 European countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erdosteine 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of acute exacerbations, spirometry parameters, COPD symptoms, QoL, safety and tolerability of erdosteine </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Belgium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spirometry, PEFR, raw, NO, specific airway resistance from plethysmography, CT to look at airway geometry, serum glutathione, enzymes, SGRQ, ABG </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lung function, exacerbation rate, QoL, cost utility</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0013" title="Ekberg‐JanssonA , LarsonM , MacNeeW , TunekA , WahlgrenL , WoutersEFM , et al. N isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. European Respiratory Journal1999;13(4):829‐34. ">Ekberg‐Jansson 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>637</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild,<br/> moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIC 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to first exacerbation, exacerbation rate, days sick (judged by patients and investigators), lung function, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate,<br/> severe to<br/> very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lysozyme 90 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation rate, time to first exacerbation, lung function, CAT</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0015" title="GrassiC , MorandiniGC . A controlled trial of intermittent oral acetylcysteine in the long‐term treatment of chronic bronchitis. European Journal of Clinical Pharmacology1976;9:393‐6. ">Grassi 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, clinical symptoms, sputum characteristics, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0016" title="GrassiC , CasaliL , CiacciaA , et al. [Terapia intervallare con l'associazione carbocisteina‐sobrerolo nella profilassi delle riacutizzazioni della bronchite cronica]. Italian Journal of Chest Disease1994;48:17‐26. ">Grassi 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbocysteine 1125 mg plus sobrerol 180 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo or alternating active‐placebo for 10 days each</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, symptoms, sputum characteristics</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0017" title="GrillageM , Barnard‐JonesK . Long‐term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. British Journal of Clinical Practice1985;39(10):395‐8. ">Grillage 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Britain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbocysteine 750 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, lung function, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0018" title="HansenNC , SkriverA , Brorsen‐RiisL , BalsløvS , EvaldT , MaltbaekN , et al. Orally administered N‐acetylcysteine may improve general well‐being in patients with mild chronic bronchitis. Respiratory Medicine1994;88:531‐5. ">Hansen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, subjective symptom scores, global well‐being, lung function, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0019" title="JacksonIM , BarnesJ , CookseyP . Efficacy and tolerability of oral acetylcysteine (fabrol) in chronic bronchitis: a double‐blind placebo controlled trial. Journal of International Medical Research1984;12:198‐206. ">Jackson 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Great Britiain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, subjective symptoms, clinical signs, radiological appearance, global well being, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 1800 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change SGRQ, CBSAS, SF‐36; post‐bronchodilator lung function</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0021" title="MalerbaM , PonticelloA , RadaeliA , BensiG , GrassiV . Effect of twelve‐months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double‐blind, randomized, multi‐center, placebo‐controlled study (the AMETHIST trial). Pulmonary Pharmacology and Therapeutics2004;17(1):27‐34. ">Malerba 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ambroxol 75 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation over first 6 months (winter period) and at 12 months, cough intensity and frequency, difficult expectoration, dyspnoea, days on antibiotics, number of working days lost </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0022" title="British Thoracic Society Research Committee. Oral N‐acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax1985;40(11):832‐5. ">McGavin 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe<br/> to very<br/> severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Great Britain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, days of antibiotics, days in bed, FEV₁, VC, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0023" title="MeisterR . Long‐term therapy with acetylcysteine retard tablets in patients with chronic bronchitis: a double‐blind, placebo controlled study. Unpublished source1986. ">Meister 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, days sick, concomitant treatment, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0024" title="BeehK‐M , BeierJ , CandlerH , WittigT . Effect of ELOM‐080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype ‐ a post‐hoc analysis of a randomized, double‐blind, placebo‐controlled clinical trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2877‐84. MeisterR , WittigT , BeuscherN , deMeyC . Efficacy and tolerability of myrtol standardized in long‐term treatment of chronic bronchitis. A double‐blind, placebo‐controlled study. Study Group Investigators. Arzneimittelforschung1999;49(4):351‐8. ">Meister 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myrtol 300 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, number of exacerbations requiring antibiotics, well‐being, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate,<br/> severe to<br/> very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erdosteine 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation frequency, duration, hospitalisation, lung function, 6MWT, SGRQ, pharmacoeconomic analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, severity of exacerbations, time to first exacerbation, days sick, lung function, patient symptoms, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0027" title="OlivieriD , ZavattiniG , TomasiniG , DaniottiS , BonsignoreG , FerraraG , et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long‐term multicenter trial. Respiration1987;51 Suppl 1:42‐51. ">Olivieri 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild, moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ambroxol retard 75 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, course of antibiotics, days sick, FEV₁, VC, symptoms, auscultatory findings, physicians' and patients' global assessments, laboratory data, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0028" title="ParrGD , HuitsonA . Oral fabrol (oral n‐acetyl‐cysteine) in chronic bronchitis. British Journal of Diseases of the Chest1987;81(4):341‐8. ">Parr 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Great Britain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, days off work, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0029" title="PelaR , CalcagniAM , SubiacoS , IsidoriP , TubaldiA , SanguinettiCM . N‐acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration1999;66(6):495‐500. ">Pela 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate,<br/> severe to<br/> very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, exacerbation severity, days sick, patient preference, lung function</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0030" title="MorganEJ , PettyTL . Summary of the national mucolytic study. Chest1990;97(Suppl):24S‐7S. PettyTL . The national mucolytic study: results of a randomized, double‐blind, placebo‐controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest1990;97(1):75‐83. ">Petty 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate,<br/> severe to<br/> very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iodinated glycerol 30 mg 4 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Investigator assessment of symptoms, patient evaluation of symptoms and global assessment, frequency of bronchodilator use, number and duration of acute exacerbations, frequency of concomitant medications, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0031" title="RasmussenJB , GlennowC . Reduction in days of illness after long‐term treatment with N‐acetylcysteine controlled‐release tablets in patients with chronic bronchitis. European Respiratory Journal1988;1:351‐5. ">Rasmussen 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, days sick evaluated by days on sick list and by patient diaries, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0032" title="RoyP , HaranA , SrinivasBN . Role of n‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication2013;45:S107. RoyP , HaranA , SrinivasBN , MjumdarP . Evaluation of effect of N‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences2014;3(1):95‐105. ">Roy 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptoms (cough, dyspnoea, sputum), lung function, haemoglobin levels, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild, moderate,<br/> severe to<br/> very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rate of exacerbations, CRQ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild, moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small airways parameters FEF<sub>25‐75%</sub>, FOT, IC, spirometry, exacerbation rate, dyspnoea, SGRQ, 6MWD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0035" title="WorthH , SchacherC , DethlefsenU . Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: a placebo‐controlled double‐blind trial. Respiratory Research2009;10(1):69. WorthH , SchacherC , DethlefsenU . Effects of concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: a placebo‐controlled double‐blind trial. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010; Vol. P538. ">Worth 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cineole 200 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations: number, severity, and duration, lung function, dyspnoea, SGRQ, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol/fluticasone propionate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV₁ %/FVC, FEV₁ % predicted, PEF% daily variation change, PaO₂, PaCO₂</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0037" title="ZhengJP , KangJ , HuangSG , ChenP , YaoWZ , YangL , et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomised placebo‐controlled trial. Lancet2008;371(9629):2013‐8. ">Zheng 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate,<br/> severe to very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbocysteine 500 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation rate, covariance‐adjusted exacerbation rate, QoL, lung function, arterial oxygen saturation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation rate, exacerbation duration, time to first exacerbation, time to recurrent exacerbation, number of participants requiring systemic corticosteroids or antibiotics or SABA, SGRQ (Chinese version), lung function, AEs (including hospitalisation or death) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>6MWD: six‐minute walk distance; AEs: adverse events; CAT: COPD assessment test; CBSAS: Chronic Bronchitis Symptoms Assessment Scale; CRQ: chronic respiratory questionnaire; FEF<sub>25‐75%</sub>: forced expiratory flow at 25%‐75% of the pulmonary volume; FEV₁: forced expiratory volume in one second; FOT: forced oscillatory technique; FVC: forced vital capacity; IC: inspiratory capacity; NAC: N‐acetylcysteine; NIC: N‐isobutyrylcysteine; PaCO₂: partial pressure of carbon dioxide; PaO₂: partial pressure of oxygen; PEF: peak expiratory flow; QoL: quality of life; SABA: short‐acting beta‐agonist; SCMC‐Lys: carbocysteine lysine salt monohydrate; SF‐36:Short Form‐36 Health Survey; SGRQ: St. George's respiratory questionnaire; VC: vital capacity. </p> </div> </div> <p>A total of 15 studies examined use of mucolytics in people with COPD only (<a href="./references#CD001287-bbs2-0003" title="BachhAA , ShahNN , BhargavaR , AhmadZ , PandeyDK , DarKA . Effect of oral N‐acetylcysteine in COPD ‐ a randomised controlled trial. JK‐Practitioner2007;14(1):12‐6. ">Bachh 2007</a>; <a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a>; <a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a>; <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a>; <a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a>; <a href="./references#CD001287-bbs2-0021" title="MalerbaM , PonticelloA , RadaeliA , BensiG , GrassiV . Effect of twelve‐months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double‐blind, randomized, multi‐center, placebo‐controlled study (the AMETHIST trial). Pulmonary Pharmacology and Therapeutics2004;17(1):27‐34. ">Malerba 2004</a>; <a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a>; <a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a>; <a href="./references#CD001287-bbs2-0029" title="PelaR , CalcagniAM , SubiacoS , IsidoriP , TubaldiA , SanguinettiCM . N‐acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration1999;66(6):495‐500. ">Pela 1999</a>; <a href="./references#CD001287-bbs2-0032" title="RoyP , HaranA , SrinivasBN . Role of n‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication2013;45:S107. RoyP , HaranA , SrinivasBN , MjumdarP . Evaluation of effect of N‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences2014;3(1):95‐105. ">Roy 2014</a>; <a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a>; <a href="./references#CD001287-bbs2-0035" title="WorthH , SchacherC , DethlefsenU . Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: a placebo‐controlled double‐blind trial. Respiratory Research2009;10(1):69. WorthH , SchacherC , DethlefsenU . Effects of concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: a placebo‐controlled double‐blind trial. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010; Vol. P538. ">Worth 2009</a>; <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a>; <a href="./references#CD001287-bbs2-0037" title="ZhengJP , KangJ , HuangSG , ChenP , YaoWZ , YangL , et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomised placebo‐controlled trial. Lancet2008;371(9629):2013‐8. ">Zheng 2008</a>; <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>). The other studies involved people with chronic bronchitis, COPD, or both. </p> <p>All but four studies were randomised, double‐blind, and placebo‐controlled and used a parallel‐group design. Blinding was not described in <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a>. Study duration ranged from 2 to 36 months. Fourteen studies had a run‐in period (<a href="./references#CD001287-bbs2-0001" title="AllegraL , CordaroCI , GrassiC . Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double‐blind, placebo‐controlled trial. Respiration1996;63:174‐80. ">Allegra 1996</a>; <a href="./references#CD001287-bbs2-0004" title="BomanG , BackerU , LarssonS , MelanderB , WahlanderL . Oral acetylcysteine reduces exacerbation rate in chronic bronchitis; report of a trial organized by the Swedish Society for Pulmonary Diseases. European Journal of Respiratory Disease1983;64:405‐15. ">Boman 1983</a>; <a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a>; <a href="./references#CD001287-bbs2-0013" title="Ekberg‐JanssonA , LarsonM , MacNeeW , TunekA , WahlgrenL , WoutersEFM , et al. N isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. European Respiratory Journal1999;13(4):829‐34. ">Ekberg‐Jansson 1999</a>; <a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a>; <a href="./references#CD001287-bbs2-0021" title="MalerbaM , PonticelloA , RadaeliA , BensiG , GrassiV . Effect of twelve‐months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double‐blind, randomized, multi‐center, placebo‐controlled study (the AMETHIST trial). Pulmonary Pharmacology and Therapeutics2004;17(1):27‐34. ">Malerba 2004</a>; <a href="./references#CD001287-bbs2-0022" title="British Thoracic Society Research Committee. Oral N‐acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax1985;40(11):832‐5. ">McGavin 1985</a>; <a href="./references#CD001287-bbs2-0024" title="BeehK‐M , BeierJ , CandlerH , WittigT . Effect of ELOM‐080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype ‐ a post‐hoc analysis of a randomized, double‐blind, placebo‐controlled clinical trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2877‐84. MeisterR , WittigT , BeuscherN , deMeyC . Efficacy and tolerability of myrtol standardized in long‐term treatment of chronic bronchitis. A double‐blind, placebo‐controlled study. Study Group Investigators. Arzneimittelforschung1999;49(4):351‐8. ">Meister 1999</a>; <a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a>; <a href="./references#CD001287-bbs2-0027" title="OlivieriD , ZavattiniG , TomasiniG , DaniottiS , BonsignoreG , FerraraG , et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long‐term multicenter trial. Respiration1987;51 Suppl 1:42‐51. ">Olivieri 1987</a>; <a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a>; <a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a>; <a href="./references#CD001287-bbs2-0037" title="ZhengJP , KangJ , HuangSG , ChenP , YaoWZ , YangL , et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomised placebo‐controlled trial. Lancet2008;371(9629):2013‐8. ">Zheng 2008</a>; <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>). Four studies were described as randomised and placebo‐controlled but not as double‐blind. One of these was labelled as 'open' (<a href="./references#CD001287-bbs2-0029" title="PelaR , CalcagniAM , SubiacoS , IsidoriP , TubaldiA , SanguinettiCM . N‐acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration1999;66(6):495‐500. ">Pela 1999</a>), and two (<a href="./references#CD001287-bbs2-0003" title="BachhAA , ShahNN , BhargavaR , AhmadZ , PandeyDK , DarKA . Effect of oral N‐acetylcysteine in COPD ‐ a randomised controlled trial. JK‐Practitioner2007;14(1):12‐6. ">Bachh 2007</a>; <a href="./references#CD001287-bbs2-0032" title="RoyP , HaranA , SrinivasBN . Role of n‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication2013;45:S107. RoyP , HaranA , SrinivasBN , MjumdarP . Evaluation of effect of N‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences2014;3(1):95‐105. ">Roy 2014</a>) were 'single‐blind' trials. The fourth was a randomised cross‐over trial (<a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a>). As a result of the potential for bias, these are reported separately in analyses of primary outcomes. </p> <p>In one study conducted in primary care practices (<a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a>), investigators compared NAC 600 mg daily versus placebo as well as inhaled fluticasone 500 μg twice daily in a three‐arm study of double‐dummy design. This review used data from NAC and placebo arms only. </p> <section id="CD001287-sec-0065"> <h5 class="title">Inclusion and exclusion criteria</h5> <p>All studies indicated that participants fulfilled criteria for chronic bronchitis, COPD, or both (except <a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a>, which has been published in abstract form only). Exclusion criteria varied, and some studies did not report whether patients with other respiratory illnesses were excluded. </p> </section> <section id="CD001287-sec-0066"> <h5 class="title">Lung function</h5> <p>All but two studies ‐ <a href="./references#CD001287-bbs2-0015" title="GrassiC , MorandiniGC . A controlled trial of intermittent oral acetylcysteine in the long‐term treatment of chronic bronchitis. European Journal of Clinical Pharmacology1976;9:393‐6. ">Grassi 1976</a> and <a href="./references#CD001287-bbs2-0028" title="ParrGD , HuitsonA . Oral fabrol (oral n‐acetyl‐cysteine) in chronic bronchitis. British Journal of Diseases of the Chest1987;81(4):341‐8. ">Parr 1987</a> ‐ reported baseline lung function using PEFR, FEV₁ or FEV₁ % predicted. When studies reported pre‐bronchodilator and post‐bronchodilator lung function, we used the latter. </p> </section> <section id="CD001287-sec-0067"> <h5 class="title">Age of participants</h5> <p>The mean age of participants ranged from 40 to 71 years. Most studies had an upper age limit for participants. </p> </section> <section id="CD001287-sec-0068"> <h5 class="title">Gender of participants</h5> <p>All but three of the studies reported the proportion of males included in the study. This ranged from 44% to 93%. In another study, "almost all" of the participants were reported as male. </p> </section> <section id="CD001287-sec-0069"> <h5 class="title">Smokers</h5> <p>All but five studies reported the percentage of current smokers or ex‐smokers, which ranged from 55% to 100%. </p> </section> <section id="CD001287-sec-0070"> <h5 class="title">Mucolytics and dose</h5> <p>In 21 studies, the mucolytic used was N‐acetylcysteine (NAC). Other treatments studied included carbocysteine (N = 3), ambroxol (N = 3), erdosteine (N = 2), sobrerol (N = 1), carbocysteine‐sobrerol (N = 1), carbocysteine‐lysine (n = 1), letosteine (N = 1), cithiolone (N = 1), iodinated glycerol (N = 1), N‐isobutyrylcysteine (NIC) (N = 1), myrtol (N = 1), and cineole and lysozyme (N = 1). </p> <p>Of the 21 studies of NAC, three used a total dose of 400 mg/day (<a href="./references#CD001287-bbs2-0002" title="Multicenter Study Group. Long‐term oral acetylcysteine in chronic bronchitis. A double‐blind controlled study. European Journal of Respiratory Disease1980;61(111 Suppl):93‐108. ">Babolini 1980</a>; <a href="./references#CD001287-bbs2-0004" title="BomanG , BackerU , LarssonS , MelanderB , WahlanderL . Oral acetylcysteine reduces exacerbation rate in chronic bronchitis; report of a trial organized by the Swedish Society for Pulmonary Diseases. European Journal of Respiratory Disease1983;64:405‐15. ">Boman 1983</a>; <a href="./references#CD001287-bbs2-0006" title="BorgiaM , SepeN , Ori‐BelomettiM , BorgiaR . Comparison between acetylcysteine and placebo in the long term treatment of chronic bronchitis [Confronto tra acetilcisteina e placebo nel trattamento a lungo termine della bronchite cronica]. Gazzetta Medica Italiana1981;140:467‐72. ">Borgia 1981</a>); 11 used a total dose of 600 mg/day (<a href="./references#CD001287-bbs2-0003" title="BachhAA , ShahNN , BhargavaR , AhmadZ , PandeyDK , DarKA . Effect of oral N‐acetylcysteine in COPD ‐ a randomised controlled trial. JK‐Practitioner2007;14(1):12‐6. ">Bachh 2007</a>; <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a>; <a href="./references#CD001287-bbs2-0015" title="GrassiC , MorandiniGC . A controlled trial of intermittent oral acetylcysteine in the long‐term treatment of chronic bronchitis. European Journal of Clinical Pharmacology1976;9:393‐6. ">Grassi 1976</a>; <a href="./references#CD001287-bbs2-0019" title="JacksonIM , BarnesJ , CookseyP . Efficacy and tolerability of oral acetylcysteine (fabrol) in chronic bronchitis: a double‐blind placebo controlled trial. Journal of International Medical Research1984;12:198‐206. ">Jackson 1984</a>; <a href="./references#CD001287-bbs2-0022" title="British Thoracic Society Research Committee. Oral N‐acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax1985;40(11):832‐5. ">McGavin 1985</a>; <a href="./references#CD001287-bbs2-0023" title="MeisterR . Long‐term therapy with acetylcysteine retard tablets in patients with chronic bronchitis: a double‐blind, placebo controlled study. Unpublished source1986. ">Meister 1986</a>; <a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a>; <a href="./references#CD001287-bbs2-0028" title="ParrGD , HuitsonA . Oral fabrol (oral n‐acetyl‐cysteine) in chronic bronchitis. British Journal of Diseases of the Chest1987;81(4):341‐8. ">Parr 1987</a>; <a href="./references#CD001287-bbs2-0029" title="PelaR , CalcagniAM , SubiacoS , IsidoriP , TubaldiA , SanguinettiCM . N‐acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration1999;66(6):495‐500. ">Pela 1999</a>; <a href="./references#CD001287-bbs2-0031" title="RasmussenJB , GlennowC . Reduction in days of illness after long‐term treatment with N‐acetylcysteine controlled‐release tablets in patients with chronic bronchitis. European Respiratory Journal1988;1:351‐5. ">Rasmussen 1988</a>; <a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a>); five used 1200 mg/day (<a href="./references#CD001287-bbs2-0018" title="HansenNC , SkriverA , Brorsen‐RiisL , BalsløvS , EvaldT , MaltbaekN , et al. Orally administered N‐acetylcysteine may improve general well‐being in patients with mild chronic bronchitis. Respiratory Medicine1994;88:531‐5. ">Hansen 1994</a>; <a href="./references#CD001287-bbs2-0032" title="RoyP , HaranA , SrinivasBN . Role of n‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication2013;45:S107. RoyP , HaranA , SrinivasBN , MjumdarP . Evaluation of effect of N‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences2014;3(1):95‐105. ">Roy 2014</a>; <a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a>; <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a>; <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>); one used 1800 mg/day (<a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a>; ); and one used 3600 mg/day (<a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>). </p> </section> <section id="CD001287-sec-0071"> <h5 class="title">Size and duration</h5> <p>Study size ranged from 12 participants in <a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a> to 1006 participants in <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>. Duration ranged from 2 months in <a href="./references#CD001287-bbs2-0030" title="MorganEJ , PettyTL . Summary of the national mucolytic study. Chest1990;97(Suppl):24S‐7S. PettyTL . The national mucolytic study: results of a randomized, double‐blind, placebo‐controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest1990;97(1):75‐83. ">Petty 1990</a> and <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a> to 36 months in <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a> and <a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a>. The mean duration of treatment, weighted by study size, was 9.4 months. Over a third of participants were enrolled in studies lasting 12 months or longer. </p> </section> <section id="CD001287-sec-0072"> <h5 class="title">Countries</h5> <p>Twelve studies were conducted only in Italy, four in the United Kingdom, four in Germany, four in China, four in several European countries, three in Scandinavia, two in India, two in the United States, and one each in The Netherlands, Belgium, and Japan. </p> </section> <section id="CD001287-sec-0073"> <h5 class="title">Funding</h5> <p>We have extracted and presented information on study funding since the 2014 update. A majority of studies included since 2014 report pharmaceutical sponsorship, with the exception of <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016,</a><a href="./references#CD001287-bbs2-0032" title="RoyP , HaranA , SrinivasBN . Role of n‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication2013;45:S107. RoyP , HaranA , SrinivasBN , MjumdarP . Evaluation of effect of N‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences2014;3(1):95‐105. ">Roy 2014,</a> and <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a>. </p> </section> </section> <section id="CD001287-sec-0074"> <h4 class="title">Excluded studies</h4> <p>We excluded 20 studies after scrutiny of the full text. See <a href="./references#CD001287-sec-0138" title="">Characteristics of excluded studies</a> for the reasons for exclusion. </p> </section> </section> <section id="CD001287-sec-0075"> <h3 class="title">Risk of bias in included studies</h3> <p>Details of our risk of bias judgements are presented in <a href="./references#CD001287-sec-0137" title="">Characteristics of included studies</a> and in an overview in <a href="#CD001287-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD001287-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001287-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001287-sec-0076"> <h4 class="title">Allocation</h4> <p>Potential for bias in most studies was regarded as unclear, in that study authors stated that the study was randomised but did not indicate how this was achieved, where it was done, or how it was concealed. Seven studies were judged to be at low risk of bias for both random sequence generation and allocation concealment (<a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a>; <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a>; <a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a>; <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>; <a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a>; <a href="./references#CD001287-bbs2-0037" title="ZhengJP , KangJ , HuangSG , ChenP , YaoWZ , YangL , et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomised placebo‐controlled trial. Lancet2008;371(9629):2013‐8. ">Zheng 2008</a>; <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>). Six studies were judged to be randomised but provided insufficient details about allocation concealment (<a href="./references#CD001287-bbs2-0001" title="AllegraL , CordaroCI , GrassiC . Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double‐blind, placebo‐controlled trial. Respiration1996;63:174‐80. ">Allegra 1996</a>; <a href="./references#CD001287-bbs2-0018" title="HansenNC , SkriverA , Brorsen‐RiisL , BalsløvS , EvaldT , MaltbaekN , et al. Orally administered N‐acetylcysteine may improve general well‐being in patients with mild chronic bronchitis. Respiratory Medicine1994;88:531‐5. ">Hansen 1994</a>; <a href="./references#CD001287-bbs2-0027" title="OlivieriD , ZavattiniG , TomasiniG , DaniottiS , BonsignoreG , FerraraG , et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long‐term multicenter trial. Respiration1987;51 Suppl 1:42‐51. ">Olivieri 1987</a>; <a href="./references#CD001287-bbs2-0028" title="ParrGD , HuitsonA . Oral fabrol (oral n‐acetyl‐cysteine) in chronic bronchitis. British Journal of Diseases of the Chest1987;81(4):341‐8. ">Parr 1987</a>; <a href="./references#CD001287-bbs2-0030" title="MorganEJ , PettyTL . Summary of the national mucolytic study. Chest1990;97(Suppl):24S‐7S. PettyTL . The national mucolytic study: results of a randomized, double‐blind, placebo‐controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest1990;97(1):75‐83. ">Petty 1990</a>; <a href="./references#CD001287-bbs2-0031" title="RasmussenJB , GlennowC . Reduction in days of illness after long‐term treatment with N‐acetylcysteine controlled‐release tablets in patients with chronic bronchitis. European Respiratory Journal1988;1:351‐5. ">Rasmussen 1988</a>). Six studies were judged to be at high risk of bias for one or both domains (<a href="./references#CD001287-bbs2-0003" title="BachhAA , ShahNN , BhargavaR , AhmadZ , PandeyDK , DarKA . Effect of oral N‐acetylcysteine in COPD ‐ a randomised controlled trial. JK‐Practitioner2007;14(1):12‐6. ">Bachh 2007</a>; <a href="./references#CD001287-bbs2-0004" title="BomanG , BackerU , LarssonS , MelanderB , WahlanderL . Oral acetylcysteine reduces exacerbation rate in chronic bronchitis; report of a trial organized by the Swedish Society for Pulmonary Diseases. European Journal of Respiratory Disease1983;64:405‐15. ">Boman 1983</a>; <a href="./references#CD001287-bbs2-0007" title="CastiglioniCL , GramoliniC . Effect of long‐term treatment with sobrerol on the exacerbations of chronic bronchitis. Respiration1986;50:202‐17. ">Castiglioni 1986</a>; <a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a>; <a href="./references#CD001287-bbs2-0029" title="PelaR , CalcagniAM , SubiacoS , IsidoriP , TubaldiA , SanguinettiCM . N‐acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration1999;66(6):495‐500. ">Pela 1999</a>; <a href="./references#CD001287-bbs2-0032" title="RoyP , HaranA , SrinivasBN . Role of n‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication2013;45:S107. RoyP , HaranA , SrinivasBN , MjumdarP . Evaluation of effect of N‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences2014;3(1):95‐105. ">Roy 2014</a>). </p> <p>Most studies reported baseline characteristics of treatment groups, which were well matched at baseline. </p> </section> <section id="CD001287-sec-0077"> <h4 class="title">Blinding</h4> <p>Most studies (N = 30) reported that the placebo was identical in appearance to the active treatment and therefore were judged to be at low risk of performance bias. Six studies were regarded as high risk, which related largely to lack of blinding, although <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a> provided no description of blinding, and so an open‐label policy must be assumed (<a href="./references#CD001287-bbs2-0003" title="BachhAA , ShahNN , BhargavaR , AhmadZ , PandeyDK , DarKA . Effect of oral N‐acetylcysteine in COPD ‐ a randomised controlled trial. JK‐Practitioner2007;14(1):12‐6. ">Bachh 2007</a>; <a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a>; <a href="./references#CD001287-bbs2-0029" title="PelaR , CalcagniAM , SubiacoS , IsidoriP , TubaldiA , SanguinettiCM . N‐acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration1999;66(6):495‐500. ">Pela 1999</a>; <a href="./references#CD001287-bbs2-0032" title="RoyP , HaranA , SrinivasBN . Role of n‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication2013;45:S107. RoyP , HaranA , SrinivasBN , MjumdarP . Evaluation of effect of N‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences2014;3(1):95‐105. ">Roy 2014</a>; <a href="./references#CD001287-bbs2-0035" title="WorthH , SchacherC , DethlefsenU . Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: a placebo‐controlled double‐blind trial. Respiratory Research2009;10(1):69. WorthH , SchacherC , DethlefsenU . Effects of concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: a placebo‐controlled double‐blind trial. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010; Vol. P538. ">Worth 2009</a>; <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a>). </p> <p>Blinding of outcome assessors was less well described, but 27 studies described adequate procedures, allowing us to judge these as having low risk of bias. Four studies were at high risk of bias and seven studies reported insufficient details about detection bias to permit a judgement. </p> </section> <section id="CD001287-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>Reported dropout ranged from 0% in <a href="./references#CD001287-bbs2-0003" title="BachhAA , ShahNN , BhargavaR , AhmadZ , PandeyDK , DarKA . Effect of oral N‐acetylcysteine in COPD ‐ a randomised controlled trial. JK‐Practitioner2007;14(1):12‐6. ">Bachh 2007,</a><a href="./references#CD001287-bbs2-0005" title="BontognaliE . Clinical effectiveness and tolerance of cithiolone in the prophylaxis of acute infective exacerbations in patients suffering from chronic bronchitis. Acta Therapeutica1991;17:155‐62. ">Bontognali 1991,</a><a href="./references#CD001287-bbs2-0009" title="CremoniniC , SpadaE , CelliniF , CioniR , GiovanniniM , PerriG , et al. I farmaci attivi sul muco nel trattamento di fondo della bronchite cronica [Pharmacotherapy which acts on mucus in long‐term treatment of chronic bronchitis]. La Clinica Terapeutica1986;116:121‐9. ">Cremonini 1986,</a> and <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a> to 37% in the three‐year BRONCUS study (<a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a>), and this rate was given as 43% in another three‐year study conducted in a general practice setting (<a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a>). When the rate exceeded 20%, we considered a high‐risk rating but also took into account whether numbers of dropouts were balanced between arms, and whether the reasons given for dropout were similar. We judged 13 studies to be at high risk (<a href="./references#CD001287-bbs2-0001" title="AllegraL , CordaroCI , GrassiC . Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double‐blind, placebo‐controlled trial. Respiration1996;63:174‐80. ">Allegra 1996</a>; <a href="./references#CD001287-bbs2-0002" title="Multicenter Study Group. Long‐term oral acetylcysteine in chronic bronchitis. A double‐blind controlled study. European Journal of Respiratory Disease1980;61(111 Suppl):93‐108. ">Babolini 1980</a>; <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a>; <a href="./references#CD001287-bbs2-0013" title="Ekberg‐JanssonA , LarsonM , MacNeeW , TunekA , WahlgrenL , WoutersEFM , et al. N isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. European Respiratory Journal1999;13(4):829‐34. ">Ekberg‐Jansson 1999</a>; <a href="./references#CD001287-bbs2-0018" title="HansenNC , SkriverA , Brorsen‐RiisL , BalsløvS , EvaldT , MaltbaekN , et al. Orally administered N‐acetylcysteine may improve general well‐being in patients with mild chronic bronchitis. Respiratory Medicine1994;88:531‐5. ">Hansen 1994</a><a href="./references#CD001287-bbs2-0019" title="JacksonIM , BarnesJ , CookseyP . Efficacy and tolerability of oral acetylcysteine (fabrol) in chronic bronchitis: a double‐blind placebo controlled trial. Journal of International Medical Research1984;12:198‐206. ">Jackson 1984</a>; <a href="./references#CD001287-bbs2-0022" title="British Thoracic Society Research Committee. Oral N‐acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax1985;40(11):832‐5. ">McGavin 1985</a>; <a href="./references#CD001287-bbs2-0023" title="MeisterR . Long‐term therapy with acetylcysteine retard tablets in patients with chronic bronchitis: a double‐blind, placebo controlled study. Unpublished source1986. ">Meister 1986</a>; <a href="./references#CD001287-bbs2-0028" title="ParrGD , HuitsonA . Oral fabrol (oral n‐acetyl‐cysteine) in chronic bronchitis. British Journal of Diseases of the Chest1987;81(4):341‐8. ">Parr 1987</a>; <a href="./references#CD001287-bbs2-0030" title="MorganEJ , PettyTL . Summary of the national mucolytic study. Chest1990;97(Suppl):24S‐7S. PettyTL . The national mucolytic study: results of a randomized, double‐blind, placebo‐controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest1990;97(1):75‐83. ">Petty 1990</a>; <a href="./references#CD001287-bbs2-0032" title="RoyP , HaranA , SrinivasBN . Role of n‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication2013;45:S107. RoyP , HaranA , SrinivasBN , MjumdarP . Evaluation of effect of N‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences2014;3(1):95‐105. ">Roy 2014</a>; <a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a>; <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>). We judged 12 studies to be at low risk as dropout either was low or had been sufficiently well described that we were confident the results of the study were unlikely to be impacted (<a href="./references#CD001287-bbs2-0003" title="BachhAA , ShahNN , BhargavaR , AhmadZ , PandeyDK , DarKA . Effect of oral N‐acetylcysteine in COPD ‐ a randomised controlled trial. JK‐Practitioner2007;14(1):12‐6. ">Bachh 2007</a>; <a href="./references#CD001287-bbs2-0005" title="BontognaliE . Clinical effectiveness and tolerance of cithiolone in the prophylaxis of acute infective exacerbations in patients suffering from chronic bronchitis. Acta Therapeutica1991;17:155‐62. ">Bontognali 1991</a>; <a href="./references#CD001287-bbs2-0007" title="CastiglioniCL , GramoliniC . Effect of long‐term treatment with sobrerol on the exacerbations of chronic bronchitis. Respiration1986;50:202‐17. ">Castiglioni 1986</a>; <a href="./references#CD001287-bbs2-0009" title="CremoniniC , SpadaE , CelliniF , CioniR , GiovanniniM , PerriG , et al. I farmaci attivi sul muco nel trattamento di fondo della bronchite cronica [Pharmacotherapy which acts on mucus in long‐term treatment of chronic bronchitis]. La Clinica Terapeutica1986;116:121‐9. ">Cremonini 1986</a>; <a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a>; <a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a>; <a href="./references#CD001287-bbs2-0016" title="GrassiC , CasaliL , CiacciaA , et al. [Terapia intervallare con l'associazione carbocisteina‐sobrerolo nella profilassi delle riacutizzazioni della bronchite cronica]. Italian Journal of Chest Disease1994;48:17‐26. ">Grassi 1994</a>; <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>; <a href="./references#CD001287-bbs2-0021" title="MalerbaM , PonticelloA , RadaeliA , BensiG , GrassiV . Effect of twelve‐months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double‐blind, randomized, multi‐center, placebo‐controlled study (the AMETHIST trial). Pulmonary Pharmacology and Therapeutics2004;17(1):27‐34. ">Malerba 2004</a>; <a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a>; <a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a>; <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a>). We judged the remaining studies to be at unclear risk because dropouts were not clearly reported or were sufficiently high to raise concern, even if numbers and reasons were balanced. </p> <p>In most of the older studies and in <a href="./references#CD001287-bbs2-0032" title="RoyP , HaranA , SrinivasBN . Role of n‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication2013;45:S107. RoyP , HaranA , SrinivasBN , MjumdarP . Evaluation of effect of N‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences2014;3(1):95‐105. ">Roy 2014</a>, analyses were performed on participants who completed the study (per protocol), whereas in more recent studies, analyses tended to be performed on an intention‐to‐treat basis. </p> </section> <section id="CD001287-sec-0079"> <h4 class="title">Selective reporting</h4> <p>Three studies were graded as high risk: two because they were unpublished (<a href="./references#CD001287-bbs2-0023" title="MeisterR . Long‐term therapy with acetylcysteine retard tablets in patients with chronic bronchitis: a double‐blind, placebo controlled study. Unpublished source1986. ">Meister 1986</a>; <a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a>), and one because study authors did not report all study outcomes (<a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a>). Most of the other studies reported sufficient details that we could make a judgement of low risk of bias. </p> </section> <section id="CD001287-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>None were noted.</p> </section> </section> <section id="CD001287-sec-0081"> <h3 class="title" id="CD001287-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD001287-tbl-0001"><b>Summary of findings for the main comparison</b> Mucolytic compared to placebo for chronic bronchitis or chronic obstructive pulmonary disease</a> </p> <section id="CD001287-sec-0082"> <h4 class="title">Mucolytic versus control</h4> <section id="CD001287-sec-0083"> <h5 class="title">Exacerbations</h5> <section id="CD001287-sec-0084"> <h6 class="title">Patients with no exacerbations during study period</h6> <p>The odds ratio (OR) for having no exacerbations over the entire study period when treatment with mucolytics was provided in double‐blind trials was increased compared with placebo (Peto OR 1.69, 95% confidence interval (CI) 1.53 to 1.88; participants = 6460; studies = 26; I² = 62%; <a href="#CD001287-fig-0005">Figure 5</a>; <a href="./references#CD001287-fig-0009" title="">Analysis 1.1</a>; moderate‐certainty evidence). This yielded a number needed to treat for an additional beneficial outcome (NNTB) of 8 (95% CI 7 to 10; <a href="#CD001287-fig-0006">Figure 6</a>). Inclusion of single‐blind studies in the analysis had a minimal impact on the pooled effect (Peto OR 1.73, 95% CI 1.56 to 1.91; participants = 6723; studies = 28; I² = 62%). We also conducted a sensitivity analysis including only the studies judged to be at low risk of selection bias; this substantially reduced the number of studies in the meta‐analysis, and the effect was attenuated (Peto OR 1.15, 95% CI 0.96 to 1.37; participants = 2353; studies = 5; I² = 40%). However, removing the eight studies included in this analysis judged to be at high risk of attrition bias had little impact on the pooled effect estimate (Peto OR 1.84, 95% CI 1.62 to 2.09; participants = 4141; studies = 20; I² = 50%). </p> <div class="figure" id="CD001287-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Mucolytic versus placebo, outcome: 1.1 Participants with no exacerbations in study period." data-id="CD001287-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mucolytic versus placebo, outcome: 1.1 Participants with no exacerbations in study period. </p> </div> </div> </div> <div class="figure" id="CD001287-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="In the control group, 39 of 100 people were free from exacerbations over 9 months (represented by green faces) compared with 52 (95% CI 49 to 55) of 100 for the mucolytic group (represented by green plus yellow faces)." data-id="CD001287-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>In the control group, 39 of 100 people were free from exacerbations over 9 months (represented by green faces) compared with 52 (95% CI 49 to 55) of 100 for the mucolytic group (represented by green plus yellow faces). </p> </div> </div> </div> <p>As heterogeneity in this result is high (I² = 62%), we carried out a post hoc subgroup analysis showing results of double‐blind trials ordered by year of publication and subgrouped by decade of publication (<a href="./references#CD001287-fig-0010" title="">Analysis 1.2</a>; <a href="#CD001287-fig-0007">Figure 7</a>). This revealed a tendency for more recent studies to provide more conservative results: studies published before 1990 (Peto OR 2.34, 95% CI 1.97 to 2.79) and between 1990 and 1999 (Peto OR 1.91, 95% CI 1.50 to 2.44) have a greater effect size than those published between 2000 and 2009 (Peto OR 1.24, 95% CI 1.01 to 1.54) or since 2010 (Peto OR 1.28, 95% CI 1.03 to 1.59). It is also notable that of the six studies with adequate allocation concealment (<a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a>; <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a>; <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>; <a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a>; <a href="./references#CD001287-bbs2-0037" title="ZhengJP , KangJ , HuangSG , ChenP , YaoWZ , YangL , et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomised placebo‐controlled trial. Lancet2008;371(9629):2013‐8. ">Zheng 2008</a>; <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>), only <a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a> reported a notable benefit of treatment in preventing exacerbations. </p> <div class="figure" id="CD001287-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Mucolytic versus placebo, outcome: 1.2 Participants with no exacerbation by decade; double‐blind trials only." data-id="CD001287-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mucolytic versus placebo, outcome: 1.2 Participants with no exacerbation by decade; double‐blind trials only. </p> </div> </div> </div> <p>We carried out a separate analysis of studies conducted during winter months only and observed a larger effect size when compared to all studies (Peto OR 2.20, 95% CI 1.93 to 2.51; participants = 4007; studies = 21; I² = 19%; <a href="./references#CD001287-fig-0011" title="">Analysis 1.3</a>). When subgrouped by dose or type of mucolytic, we did not observe a consistent effect (I<sup>2</sup> 62%, <a href="./references#CD001287-fig-0012" title="">Analysis 1.4</a>). Overall we observed significant benefits over placebo for lower doses of NAC and carbocysteine,. The "other" mucolytic category also showed benefit compared to placebo; this category included studies of ambroxol (N = 2); erdosteine (N = 1); letosteine (N = 1); sobrerol (N = 1); myrtol (N = 1); and cineole (N = 1). </p> <p>Studies with participants with on average better lung function at baseline found greater benefit from mucolytics when compared to those with on average poorer lung function (&gt; 50% predicted vs ≤ 50% predicted; test for subgroup differences: Chi² = 4.14, df = 1 (P = 0.04; I² = 75.9%; <a href="./references#CD001287-fig-0013" title="">Analysis 1.5</a>). However, this result should be interpreted with caution as the poorer lung function subgroup contained only four studies. </p> <p>Studies of greater duration on average had a lesser effect than those of shorter duration; the OR for studies ≥ 12 months was 1.16 (95% 0.98 to 1.37) compared to 2.14 (95% CI 1.62 to 2.82) and 2.20 (95% CI 1.91 to 2.54) for up to three months and three to 12 months, respectively (test for subgroup differences: Chi² = 35.72, df = 2 (P &lt; 0.00001; <a href="./references#CD001287-fig-0014" title="">Analysis 1.6</a>). </p> <p>We also observed a larger effect among studies conducted in Italy compared to those not conducted in Italy (test for subgroup differences: Chi² = 25.94, df = 1 (P &lt; 0.00001; <a href="./references#CD001287-fig-0015" title="">Analysis 1.7</a>). This analysis was carried out as it has been noted in the past that some of the earlier trials of mucolytics in Italy were reporting greater effects than trials conducted elsewhere, We also noted a larger effect in those studies in which history of an exacerbation was not a requirement for study entry compared to those where it was (test for subgroup differences: Chi² = 12.51, df = 1 (P = 0.0004; <a href="./references#CD001287-fig-0016" title="">Analysis 1.8</a>). </p> <p>A funnel plot for this outcome gave no clear indication of publication bias (<a href="#CD001287-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD001287-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.1 Participants with no exacerbations in study period." data-id="CD001287-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.1 Participants with no exacerbations in study period. </p> </div> </div> </div> </section> <section id="CD001287-sec-0085"> <h6 class="title">Exacerbations in patients by use of concomitant inhaled corticosteroids (ICS)</h6> <p>Subgrouping studies for this outcome according to whether ICS were or were not allowed (or unclear) did not suggest that this was an important effect modifier, and the test for subgroup differences was negative (test for subgroup differences: Chi² = 1.64, df = 2; (P = 0.44; <a href="./references#CD001287-fig-0017" title="">Analysis 1.9</a>). </p> </section> <section id="CD001287-sec-0086"> <h6 class="title">Time to first exacerbation</h6> <p>Sufficient data with which to perform a meta‐analysis are not yet available for this clinically relevant outcome. Post hoc analysis of the EQUALIFE study revealed that participants given erdosteine had a significantly longer time until their first exacerbation compared with those given placebo, with a hazard ratio of 0.639 (95% CI 0.416 to 0.981) (<a href="./references#CD001287-bbs2-0063" title="BallabioM , NicolaM , MorettiM . Long‐term use of antioxidant mucolytic erdosteine is especially beneficial in patient with more severe COPD. European Respiratory Society 18th Annual Congress; 2008 Oct 3‐7; Berlin. 2008:abstract ERS08L1_678. ">Ballabio 2008</a>). Longer time to first exacerbation was also reported by <a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a>. In that study, participants with COPD treated with NAC had a mean of 139 days (SD 68) to first exacerbation versus 108 (SD 79) days for those given placebo (P &lt; 0.05). More recently, <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>, <a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a>, and <a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a> reported time to first exacerbation. <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a> reported no differences between time to first exacerbation in NAC‐ or placebo‐treated groups, but time to second and third exacerbations was shorter in the placebo group. <a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a> reported increased time to first exacerbation in the erdosteine group compared to the placebo group, but this did not reach statistical significance (Kaplan–Meier plot of probability, P = 0.07). <a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a> reported the median time to first exacerbation as 179 days in the lysozyme group and 210 days in the placebo group (hazard ratio 1.06; P = 0.626). </p> </section> <section id="CD001287-sec-0087"> <h6 class="title">Number of exacerbations per patient per month</h6> <p>We calculated and meta‐analysed the number of exacerbations per patient per month as a primary outcome in previous versions of this review. For the 2019 update, we decided not to update these analyses due to concerns about high levels of heterogeneity, the need to impute much of the data, and the likely skew of this measure. Instead, we present the data in a table (<a href="./references#CD001287-fig-0018" title="">Analysis 1.10</a>). The mean difference in number of exacerbations per patient per month favoured the mucolytic intervention in most studies, but this finding should be interpreted with caution in light of the caveats already mentioned. </p> </section> </section> <section id="CD001287-sec-0088"> <h5 class="title">Number of days of disability per participant per month ('sick days')</h5> <p>We were able to meta‐analyse data from nine studies, showing a significant reduction of 0.43 days of disability per participant per month with mucolytic therapy (95% CI ‐0.56 to ‐0.30; 9 studies, 2259 participants; <a href="./references#CD001287-fig-0019" title="">Analysis 1.11</a>; moderate‐certainty evidence) compared with placebo. This finding was associated with a high level of heterogeneity (I² = 61%). </p> <p>The following studies reported information that we were unable to meta‐analyse. <a href="./references#CD001287-bbs2-0008" title="CeglaUH . Long‐term treatment of chronic bronchitis for two years with ambroxol (Mucosolvan) retard capsules. Results of a double blind trial including 180 patients [Langzeittherapie uber 2 Jahre mit Ambroxol (Mucosolvan) Retardkapseln bei Patienten mit chronischer Bronchitis. Ergebnisse einer Doppelblindstudie an 180 Patienten]. Praxis Klinik der Pneumologie1988;42:715‐21. ">Cegla 1988</a> reported total days off sick per group over the two years and noted that this did not differ significantly between the two treatments (1071 days in the ambroxol group and 979 in the placebo group over two years; participants = 180). <a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a> reported the cumulative exacerbation days per group as 462 days in the NAC group and 776 days in the placebo group over eight months (participants = 295). <a href="./references#CD001287-bbs2-0030" title="MorganEJ , PettyTL . Summary of the national mucolytic study. Chest1990;97(Suppl):24S‐7S. PettyTL . The national mucolytic study: results of a randomized, double‐blind, placebo‐controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest1990;97(1):75‐83. ">Petty 1990</a> reported the mean duration in days of exacerbations between week 4 and week 8 of the trial. The mean duration in the iodinated glycerol group was 6.3 compared to 10.2 in the placebo group; the P value for the difference was reported as 0.029 (participants = 376). <a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a> did not report total 'sick days'; however, investigators did report the numbers of individuals losing workdays: seven in the erdosteine group and 10 in the placebo group, for a mean number of days lost per person of 0.8 and 1.1, respectively. </p> <p>In the three studies that reported it, a mean reduction of 0.53 days on antibiotics per participant per month was observed (95% CI ‐0.76 to ‐0.31; 3 studies; 714 participants; <a href="./references#CD001287-fig-0020" title="">Analysis 1.12</a>). These were older studies that included participants with chronic bronchitis. In the study of <a href="./references#CD001287-bbs2-0024" title="BeehK‐M , BeierJ , CandlerH , WittigT . Effect of ELOM‐080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype ‐ a post‐hoc analysis of a randomized, double‐blind, placebo‐controlled clinical trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2877‐84. MeisterR , WittigT , BeuscherN , deMeyC . Efficacy and tolerability of myrtol standardized in long‐term treatment of chronic bronchitis. A double‐blind, placebo‐controlled study. Study Group Investigators. Arzneimittelforschung1999;49(4):351‐8. ">Meister 1999</a>, 6/31 (52%) participants in the myrtol group with exacerbations needed antibiotics, compared with 30/49 (61%) in the placebo group. Courses of antibiotics were longer in the placebo group. The percentage of participants who needed antibiotics for longer than seven days was 37% in the myrtol group and 77% in the placebo group. <a href="./references#CD001287-bbs2-0021" title="MalerbaM , PonticelloA , RadaeliA , BensiG , GrassiV . Effect of twelve‐months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double‐blind, randomized, multi‐center, placebo‐controlled study (the AMETHIST trial). Pulmonary Pharmacology and Therapeutics2004;17(1):27‐34. ">Malerba 2004</a> reported no differences between ambroxol and placebo in terms of duration of courses of antibiotic treatment, working days lost, or number of days of hospitalisation (no data given). <a href="./references#CD001287-bbs2-0078" title="MorettiM , NicolaM . Prevention of COPD exacerbations and reduction of health care utilization with erdosteine. European Respiratory Journal2007;30(Suppl 51):557s. ">Moretti 2007</a> used post hoc analyses to report that compared with placebo, erdosteine use was associated with relatively fewer antibiotic courses (32%) and shorter durations of treatment (15%). The mean number of antibiotic courses per participant treated with erdosteine was also lower than for those given placebo (0.5 (SD 0.7) vs 0.7 (SD 0.7); P = 0.045). </p> </section> <section id="CD001287-sec-0089"> <h5 class="title">Lung function</h5> <section id="CD001287-sec-0090"> <h6 class="title">FEV₁</h6> <p>Fourteen studies reported FEV₁ in L at the end of the study. The pooled effect favours mucolytics over placebo, but the effect size is small (mean difference (MD) 0.04 L, 95% CI 0.01 to 0.07; participants = 3310; <a href="./references#CD001287-fig-0021" title="">Analysis 1.13</a>; moderate‐certainty evidence). We observed substantial heterogeneity in this outcome (I² = 70%), and so results should be interpreted with caution. Furthermore, this analysis includes data from the <a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a> study, which reported a significant difference (&gt; 300 mL) between mucolytic and placebo groups at the end of the study; however the mucolytic group had higher baseline lung function, and the net change was therefore closer to 200 mL. If this study is removed from the analysis, a significant difference between groups is no longer observed and heterogeneity is removed. </p> <p><a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a> reported FEV₁ change from baseline in L but without variance, and so we were unable to include the results in the meta‐analysis. Trialists reported 0.225 L improvement in the NAC group (n = 33), compared to 0.062 L in the placebo group (n = 47). </p> <p>Of note, two three‐year studies are included in this analysis. The BRONCUS study of <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a> found no differences between NAC‐treated and placebo‐treated groups over three years in terms of decline in FEV₁, FVC, or diffusing capacity of the lung for carbon monoxide (DLCO). FEV₁ declined by 54 mL and 47 mL, respectively, in the two groups. Study authors reported possible benefit of NAC for functional residual capacity (FRC), with a greater reduction in this measure. The difference was ‐0.374 L (SD 1.03; P &lt; 0.01) for NAC‐treated participants, whereas for those treated with placebo, a decrease of only 0.008 L was reported. The other three‐year study found no differences between groups in lung function at the end of the study (<a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a>). In the NAC‐treated group, FEV₁ declined by 64 mL, and in the placebo group, by 60 mL. The decline in FVC was 79 mL and 65 mL, respectively. </p> <p>In the HIACE study of <a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a>, a significantly higher mean FEV₁ was reported for the NAC group at the end of the study, but this reflected differences at baseline, with no significant differences in the amount of change reported between groups. On the other hand, researchers reported significantly greater changes in the NAC group than in the placebo group for two measures of small airways function: forced expiratory flow at 25% to 50% (FEF<sub>25‐50</sub>) (P = 0.037) and forced oscillation technique (FOT) (P = 0.04), as well as for airways resistance (P = 0.01). </p> </section> <section id="CD001287-sec-0091"> <h6 class="title">Percent predicted FEV₁</h6> <p>This outcome was reported by only four studies. Although the pooled effect favours mucolytics, this is driven by one study: <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a>, which was not blinded (MD 4.79, 95% CI 1.97 to 7.62; participants = 414; <a href="./references#CD001287-fig-0022" title="">Analysis 1.14</a>), and again, we detected substantial heterogeneity (I² = 89%). </p> </section> <section id="CD001287-sec-0092"> <h6 class="title">Peak expiratory flow rate</h6> <p>Peak expiratory flow rate was reported by one study only (<a href="./references#CD001287-bbs2-0017" title="GrillageM , Barnard‐JonesK . Long‐term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. British Journal of Clinical Practice1985;39(10):395‐8. ">Grillage 1985</a>). The result favours mucolytics but is very uncertain (MD 19.00, 95% CI ‐22.70 to 60.70; participants = 109; <a href="./references#CD001287-fig-0023" title="">Analysis 1.15</a>). </p> </section> <section id="CD001287-sec-0093"> <h6 class="title">Forced vital capacity</h6> <p>Twelve studies reported this outcome, and the pooled effect revealed benefit of 50 mL of mucolytics over placebo (MD 0.05, 95% CI ‐0.00 to 0.10; participants = 3127; I² = 0%; <a href="./references#CD001287-fig-0024" title="">Analysis 1.16</a>), but the confidence interval includes no difference between groups. </p> <p>In summary, it is likely that if mucolytics affect disease progression in chronic bronchitis or COPD, changes are very small and are confined to as‐yet small and undefined subgroups. </p> </section> </section> <section id="CD001287-sec-0094"> <h5 class="title">Adverse effects</h5> <p>The meta‐analysis of total numbers of adverse effects favours mucolytic treatment, but with some heterogeneity (OR 0.84, 95% CI 0.74 to 0.94; I² = 46% participants = 7264; studies = 24; <a href="./references#CD001287-fig-0025" title="">Analysis 1.17</a>; moderate‐certainty evidence). If a random‐effects model is used, this finding is less precise and the confidence interval includes no difference (OR 0.83, 95% CI 0.69 to 1.00). </p> <p>Moreover, this analysis does not include data from several large studies. <a href="./references#CD001287-bbs2-0028" title="ParrGD , HuitsonA . Oral fabrol (oral n‐acetyl‐cysteine) in chronic bronchitis. British Journal of Diseases of the Chest1987;81(4):341‐8. ">Parr 1987</a> reported 1263 events in 258 participants in the mucolytics group (mean 4.9 per participant) and 1202 events in 268 participants in the placebo group (mean 4.5 per participant). <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a> reported 1428 events in 256 participants in the mucolytics group (mean 5.58 per participant) and 1381 events among 267 participants in the placebo group (mean 5.17 per participant). None were thought to be drug‐related. Similar numbers in each group were admitted to hospital (55 and 69, respectively). Another study described 54 events in 59 participants in the mucolytic group and 66 events in 57 participants in the placebo group (<a href="./references#CD001287-bbs2-0031" title="RasmussenJB , GlennowC . Reduction in days of illness after long‐term treatment with N‐acetylcysteine controlled‐release tablets in patients with chronic bronchitis. European Respiratory Journal1988;1:351‐5. ">Rasmussen 1988</a>). <a href="./references#CD001287-bbs2-0024" title="BeehK‐M , BeierJ , CandlerH , WittigT . Effect of ELOM‐080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype ‐ a post‐hoc analysis of a randomized, double‐blind, placebo‐controlled clinical trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2877‐84. MeisterR , WittigT , BeuscherN , deMeyC . Efficacy and tolerability of myrtol standardized in long‐term treatment of chronic bronchitis. A double‐blind, placebo‐controlled study. Study Group Investigators. Arzneimittelforschung1999;49(4):351‐8. ">Meister 1999</a> reported 201 adverse effects in 122 participants in the mucolytic group (1.65 per participant) and 170 adverse effects in 124 participants in the placebo group (1.37 per participant). These studies could not be included in the meta‐analysis because event rates exceeded numbers included in the treatment groups. <a href="./references#CD001287-bbs2-0021" title="MalerbaM , PonticelloA , RadaeliA , BensiG , GrassiV . Effect of twelve‐months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double‐blind, randomized, multi‐center, placebo‐controlled study (the AMETHIST trial). Pulmonary Pharmacology and Therapeutics2004;17(1):27‐34. ">Malerba 2004</a> also reported no greater risk of events and no greater severity of events with mucolytic treatment compared with placebo. </p> </section> <section id="CD001287-sec-0095"> <h5 class="title">Hospitalisation</h5> <p>Comparative data were provided by five studies (<a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a>; <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>; <a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a>; <a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a>; <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>). The Peto OR for hospitalisation with mucolytic treatment compared with placebo was 0.68 (95% CI 0.52 to 0.89; participants = 1833; <a href="./references#CD001287-fig-0026" title="">Analysis 1.18</a>; moderate‐certainty evidence); however, moderate heterogeneity in this result was observed (I² = 43%), and benefit was seen in only the two smaller studies (<a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a>; <a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a>). <a href="./references#CD001287-bbs2-0021" title="MalerbaM , PonticelloA , RadaeliA , BensiG , GrassiV . Effect of twelve‐months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double‐blind, randomized, multi‐center, placebo‐controlled study (the AMETHIST trial). Pulmonary Pharmacology and Therapeutics2004;17(1):27‐34. ">Malerba 2004</a> reported no significant differences in hospitalisation rates but did not provide data. <a href="./references#CD001287-bbs2-0003" title="BachhAA , ShahNN , BhargavaR , AhmadZ , PandeyDK , DarKA . Effect of oral N‐acetylcysteine in COPD ‐ a randomised controlled trial. JK‐Practitioner2007;14(1):12‐6. ">Bachh 2007</a> reported a significant reduction (P &lt; 0.05) in hospitalisation when four months of NAC treatment was provided, with 55 hospitalisations reported for 50 participants in the control group but for only 37 of 50 in the treated group. As presented, these data cannot be included in the meta‐analysis because the number of events exceeds the number of participants in the control group. If a conservative estimate of hospitalisations in the control group is made by entering them as 50 (not 55), the beneficial effect of mucolytics for hospitalisation is greater (OR 0.62, 95% CI 0.48 to 0.80) but heterogeneity is increased (I² = 76%). Mucolytics may be associated with a small decrease in hospitalisations. </p> <p>Days in hospital were reported by <a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a>. In this study, participants taking erdosteine spent 70 days in hospital, compared with 163 days for the placebo group (P = 0.04). This represented a mean of 1.1 days per treated participant compared with 2.7 days per control participant. </p> </section> <section id="CD001287-sec-0096"> <h5 class="title">Mortality</h5> <p>Eleven studies reported on numbers of deaths in mucolytic‐treated and placebo groups, revealing no significant differences, but the confidence interval is wide (Peto OR 0.98, 95% CI 0.51 to 1.87; participants = 3527; <a href="./references#CD001287-fig-0027" title="">Analysis 1.19</a>; moderate‐certainty evidence). As no deaths were reported in either group in <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>, <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a>, or <a href="./references#CD001287-bbs2-0037" title="ZhengJP , KangJ , HuangSG , ChenP , YaoWZ , YangL , et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomised placebo‐controlled trial. Lancet2008;371(9629):2013‐8. ">Zheng 2008</a>, this information could not be incorporated into the meta‐analysis. </p> </section> <section id="CD001287-sec-0097"> <h5 class="title">Health‐related quality of life</h5> <p>Although many studies reported participant and/or physician global assessments of well‐being, only ten used validated tools to evaluate health‐related quality of life (HRQoL) among participants with COPD. In nine studies, investigators used the St George's Respiratory Questionnaire (SGRQ; <a href="./references#CD001287-bbs2-0074" title="JonesPW , QuirkFH , BaveystockCM , LittlejohnsP . A self‐complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. American Review of Respiratory Disease1992;145(6):1321‐7. ">Jones 1992</a>) (<a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a>; <a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a>; <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a>; <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>; <a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a>; <a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a>; <a href="./references#CD001287-bbs2-0035" title="WorthH , SchacherC , DethlefsenU . Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: a placebo‐controlled double‐blind trial. Respiratory Research2009;10(1):69. WorthH , SchacherC , DethlefsenU . Effects of concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: a placebo‐controlled double‐blind trial. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010; Vol. P538. ">Worth 2009</a>; <a href="./references#CD001287-bbs2-0037" title="ZhengJP , KangJ , HuangSG , ChenP , YaoWZ , YangL , et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomised placebo‐controlled trial. Lancet2008;371(9629):2013‐8. ">Zheng 2008</a>; <a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a>). <a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a> used the Chronic Respiratory Questionnaire (CRQ; <a href="./references#CD001287-bbs2-0072" title="GuyattGH , BermanLB , TownsendM , PugsleySO , ChambersLW . A measure of quality of life for clinical trials in chronic lung disease. Thorax1987;42(10):773‐88. ">Guyatt 1987</a>). In <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>, trialists reported the Short Form‐36 (SF‐36) as well as SGRQ, and in <a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a>, trialists reported the COPD Assessment Test (CAT). </p> <p>The SGRQ total score is derived from scores on three subscales ‐ symptoms, activities, and impacts ‐ to yield a score out of 100 (<a href="./references#CD001287-bbs2-0074" title="JonesPW , QuirkFH , BaveystockCM , LittlejohnsP . A self‐complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. American Review of Respiratory Disease1992;145(6):1321‐7. ">Jones 1992</a>). A well person has respiratory disease scores around 7 (<a href="./references#CD001287-bbs2-0074" title="JonesPW , QuirkFH , BaveystockCM , LittlejohnsP . A self‐complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. American Review of Respiratory Disease1992;145(6):1321‐7. ">Jones 1992</a>). Lower scores indicate better quality of life. </p> <p>We were able to combine total scores on the SGRQ for seven studies at the end of the treatment period. Although the pooled result favoured mucolytics over placebo, the confidence interval included no difference (MD ‐1.37, 95% CI ‐2.85 to 0.11; studies = 7, participants = 2721; <a href="./references#CD001287-fig-0028" title="">Analysis 1.20</a>; moderate‐certainty evidence). Considerable heterogeneity among studies was apparent (I² = 64%). This effect does not meet the minimum clinically important difference of ‐4 units on the SGRQ (<a href="./references#CD001287-bbs2-0075" title="JonesPW . St. George's Respiratory Questionnaire: MCID. COPD2005;2(1):75‐9. ">Jones 2005</a>). However it is not possible to assess the impact of mucolytics at a population level without performing a responder analysis, which we have been unable to do. </p> <p>The analysis includes data from the three‐year <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a> study of 600 mg NAC daily, in which participants were evaluated with the SGRQ, although for technical reasons only about 80% of participants completed the questionnaire. During the first year of the study, participants in both treatment and placebo groups showed significantly improved scores on both scales, with no significant differences between groups (‐3.76 units on NAC and ‐4.95 units on placebo; difference between groups 1.18; P = 0.358, as reported in the text of the paper). In the second year, this improvement tailed off again, with no differences noted between treatment groups. More participants given placebo withdrew from the trial, and dropouts had a worse SGRQ score than those who remained in the study. We have used data provided by study authors as obtained from the mixed‐effects model used in this study. In a one‐year study of a higher dose of NAC (600 mg twice daily; <a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a>), no significant difference was observed between groups for SGRQ. </p> <p>In <a href="./references#CD001287-bbs2-0037" title="ZhengJP , KangJ , HuangSG , ChenP , YaoWZ , YangL , et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomised placebo‐controlled trial. Lancet2008;371(9629):2013‐8. ">Zheng 2008</a>, baseline SGRQ scores were well matched among groups. After 12 months of treatment, changes in SGRQ total scores from baseline amounted to ‐4.06 units in the carbocysteine group and ‐0.05 in the placebo group, but these values did not represent a statistically significant difference between groups (P = 0.13). A very large difference in SGRQ symptom domain results between the carbocysteine group (‐11.34 units) and the placebo group (‐3.54 units; P = 0.004) remains unexplained. Results from the single measurement obtained at one year in this study contrast with multiple measurements taken in <a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a>, by which no significant differences in symptom scores between NAC and placebo were found over time. </p> <p>In <a href="./references#CD001287-bbs2-0035" title="WorthH , SchacherC , DethlefsenU . Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: a placebo‐controlled double‐blind trial. Respiratory Research2009;10(1):69. WorthH , SchacherC , DethlefsenU . Effects of concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: a placebo‐controlled double‐blind trial. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010; Vol. P538. ">Worth 2009</a>, the mean score change at six months from baseline was ‐4.3 in the placebo group and ‐9.9 in the cineole group (P = 0.06). However, we judged this study to be at high risk of selection bias. </p> <p>In the recent one‐year <a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a> study of erdosteine, trialists reported improvements in SGRQ in both intervention and control groups but no differences between groups. Similarly, in the eight‐month <a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a> study of erdosteine, participants completed both SF‐36 and the SGRQ. The erdosteine‐treated group showed significant improvement in all domains of the SGRQ, as well as in total score, and no differences between treated and placebo groups were reported. Data from <a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a> were not suitable for inclusion in <a href="./references#CD001287-fig-0028" title="">Analysis 1.20</a>. </p> <p>In the three‐year study of NAC versus placebo (<a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a>), the CRQ was used. Groups were well matched at baseline, with evident improvement in both groups, particularly over the first year, but this never exceeded the 0.5 unit threshold regarded as clinically significant (<a href="./references#CD001287-bbs2-0072" title="GuyattGH , BermanLB , TownsendM , PugsleySO , ChambersLW . A measure of quality of life for clinical trials in chronic lung disease. Thorax1987;42(10):773‐88. ">Guyatt 1987</a>). At the end of the study, no significant differences in CRQ total scores were reported between groups (P = 0.306). </p> <p>In <a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a>, CAT scores were reported. Trialists reported that quality of life in both the lysozyme group and the placebo group improved according to this measure; improvement was greater in the lysozyme group at all time points, and the difference was significant at 24 weeks but did not remain so at 52 weeks (MD ‐0.90, 95% CI ‐2.22 to 0.42; participants = 340; studies = 1, <a href="./references#CD001287-fig-0029" title="">Analysis 1.21</a>). </p> <p>Thus, considerable variation can be seen in evidence related to HRQoL, and we are not able to assess whether mucolytics had a clinically important effect on this outcome. Furthermore, and in keeping with the exacerbation outcome, more recent studies have tended to provide more conservative estimates of the impact of mucolytics on quality of life. </p> </section> </section> <section id="CD001287-sec-0098"> <h4 class="title">Systemic thiol donor versus control</h4> <p>One study investigated a systemic thiol donor, N‐isobutyrylcysteine (NIC), versus control (<a href="./references#CD001287-bbs2-0013" title="Ekberg‐JanssonA , LarsonM , MacNeeW , TunekA , WahlgrenL , WoutersEFM , et al. N isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. European Respiratory Journal1999;13(4):829‐34. ">Ekberg‐Jansson 1999</a>). This trial randomised more than 600 participants with chronic bronchitis. There was no clear difference between groups for the number of participants who remained exacerbation‐free (Peto OR 1.01, 95% CI 0.74 to 1.39; participants = 628; <a href="./references#CD001287-fig-0030" title="">Analysis 2.1</a>), the number of exacerbations per participant per month (MD 0.01; 95% CI ‐0.02 to 0.04), or days of disability per participant per month (MD ‐0.18, 95% CI ‐0.82 to 0.46; participants = 628; <a href="./references#CD001287-fig-0032" title="">Analysis 2.3</a>). Participants in the intervention group experienced more adverse events, but the confidence interval included no difference (Peto OR 1.39, 95% CI 0.98 to 1.95; participants = 628; <a href="./references#CD001287-fig-0033" title="">Analysis 2.4</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001287-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001287-sec-0099"></div> <section id="CD001287-sec-0100"> <h3 class="title" id="CD001287-sec-0100">Summary of main results</h3> <p>The previous update of this review was performed in 2015 (<a href="./references#CD001287-bbs2-0095" title="PooleP , ChongJ , CatesCJ . Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD001287.pub5] ">Poole 2015</a>). Since that time, a further four studies that were eligible for inclusion have been conducted (<a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a>; <a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a>; <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>; <a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a>). The present update strengthens findings from our previous reviews indicating that participants given a mucolytic agent for an average of nine months are more likely to be exacerbation‐free during that time (Peto odds ratio (OR) 1.73, 95% confidence interval (CI) 1.56 to 1.91). For one participant to be exacerbation‐free, eight (95% CI 7 to 10) had to be treated for at least nine months. Mucolytics may be associated with a reduction of approximately a half‐day of disability per participant per month, but the result is heterogeneous (mean difference (MD) ‐0.43, 95% CI ‐0.56 to ‐0.30; I² = 61%). Three studies reported days on antibiotics per participant per month, and the pooled result indicated benefit of mucolytics (MD ‐0.53, 95% CI ‐0.76 to ‐0.31). </p> <p>Mucolytics may be associated with a decrease in hospitalisations, although this finding is based on data from only five studies (Peto OR 0.68, 95% CI 0.52 to 0.89). With the addition of newer studies, certainty that mucolytics do not have a substantial impact on lung function decline or mortality is increasing. Mucolytics may be associated with a reduction in all adverse events, but the effect estimate includes the possibility of no difference between groups (OR 0.83, 95% CI 0.69 to 1.00). The impact on quality of life as measured by the total St. George's Respiratory Questionnaire (SGRQ) score is smaller than the minimal clinically important difference (MCID) of 4 units and also includes the possibility of no differences between groups (MD ‐1.37, 95% CI ‐2.85 to 0.11). Furthermore, we cannot be certain about the population effect, as we were unable to carry out a responder analysis. </p> <p>For many outcomes ‐ primary and secondary ‐ significant heterogeneity has been noted among studies; therefore the results do need to be interpreted with particular caution. The only outcomes for which heterogeneity among trials was not significant were days on antibiotics, forced vital capacity (FVC), and death during the study period. To explore causes of heterogeneity for the primary outcome of exacerbations, we performed subgroup analyses according to study date, baseline forced expiratory volume in one second (FEV₁) (as % predicted), type of mucolytic, dose of mucolytic, duration of therapy, whether participants were included because they had a history of exacerbations, whether concomitant inhaled steroids were used, and the country in which the study was conducted. Heterogeneity was generally less among trials with winter treatment only and those using the same dose of N‐acetylcysteine (NAC). </p> <p>The tendency for participants given mucolytics to be more likely to be exacerbation‐free was seen in all studies except <a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a> and <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a>. <a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a> was the first study that found an increased number of exacerbations in the mucolytic‐treated group compared with the placebo‐treated group; however, this difference was not statistically significant. The exacerbation rate was generally low in this study, and data were skewed by two participants in the NAC‐treated group who had very frequent exacerbations. Additionally, this study reported a high dropout rate (43%). <a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a> also reported increased exacerbations in the mucolytic group, but the result was very imprecise and was reported in the context of a study stopped at eight weeks due to safety concerns after only 51 participants were recruited. </p> <p>However, when we performed a post hoc investigation comparing more recent study results versus those from previous decades, we found a clear reduction in the effects of treatment in more recent studies (see <a href="#CD001287-fig-0007">Figure 7</a>; I² = 89.7% between subgroups). Although all studies included in this analysis were placebo‐controlled, and most were double‐blind, the older studies were more difficult to judge in terms of bias (see <a href="#CD001287-fig-0004">Figure 4</a>), and this may have led to an overestimation of treatment effect. Therefore we have a reduced level of confidence in the overall treatment effect estimate. On the other hand, internal consistency is evident in the findings, in that the effect on exacerbations rate is accompanied by a reduction in hospitalisations and a reduction in both days of disability and days on antibiotics. </p> <p>Theoretical reasons have been proposed to explain why mucolytics may modify disease in ways other than by reducing exacerbations (i.e. through antioxidant and thiol donor effects). More recent studies have sought to explore whether the decline in FEV₁ over time is changed by mucolytics. NAC has been used at higher doses or for longer durations without providing additional benefits, although this may be due to insufficient power to detect a difference. The reduction in exacerbation rates seen with NAC was virtually identical to that observed with other mucolytics examined as a group. The mechanisms responsible for the benefits of mucolytic treatment for exacerbation rates and days of disability cannot be identified by this review. However, lack of effect of N‐isobutyrylcysteine (NIC) (a thiol donor with antioxidant properties) on exacerbation rates or days sick raises the possibility that the actions of NAC as a thiol donor are less important in the reduction of exacerbations. </p> <p>We found no evidence to suggest that mucolytics are unsafe, and findings indicate that they do not adversely affect quality of life, even though medicines need to be taken at least once a day. </p> </section> <section id="CD001287-sec-0101"> <h3 class="title" id="CD001287-sec-0101">Overall completeness and applicability of evidence</h3> <p>This review has now been updated substantively seven times. Through the process of iterative searches, we are confident that we have identified almost all the major studies with mucolytics as the intervention. </p> <p>Over time, with a steady increase in the numbers of studies published, even though a significant treatment effect of mucolytics on exacerbations has always been observed, the size of this effect has decreased from that described in the original report. This trend may be observed in <a href="#CD001287-fig-0007">Figure 7</a>, where studies have been separated by decades of publication. </p> <p>We have considered below two factors that may be contributing to this observation.</p> <section id="CD001287-sec-0102"> <h4 class="title">Improved study design, execution, and reporting over the years</h4> <p>Confidence intervals are narrower, and consequently greater weight is afforded to more recent studies. The forest plot in <a href="#CD001287-fig-0007">Figure 7</a> has been arranged in subgroups by date and shows this trend. Part of the explanation is that more recent studies, on average, have been larger than earlier ones. Another consideration is that publication bias may have influenced reporting of results of earlier trials. This is suggested by asymmetrical funnel plots in <a href="./references#CD001287-fig-0019" title="">Analysis 1.11</a> and <a href="./references#CD001287-fig-0021" title="">Analysis 1.13</a> (<a href="./full#CD001287-fig-0001">Figure 1</a> and <a href="./full#CD001287-fig-0002">Figure 2</a>). </p> <p>Furthermore, tighter definitions of chronic obstructive pulmonary disease (COPD) have been used in later studies, which have generally included patients with, at most, moderate disease. To be included in earlier studies, patients needed only to have symptoms of chronic bronchitis, which is a clinical diagnosis. Furthermore, fewer dropouts in the intervention groups of longer studies might dilute any treatment effect, as those remaining in the study have a longer period over which to have an exacerbation recorded. Finally, as was mentioned previously, older studies may be at greater risk of selection bias, which may have inflated estimates of the treatment effect. </p> </section> <section id="CD001287-sec-0103"> <h4 class="title">Improved COPD care</h4> <p>Comprehensive management of COPD now includes support for smoking cessation, vaccination, pulmonary rehabilitation, and use of inhaled corticosteroids (ICS), long‐acting beta‐agonists (LABAs), and anticholinergic agents (<a href="./references#CD001287-bbs2-0069" title="Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. goldcopd.org/wp‐content/uploads/2018/11/GOLD‐2019‐v1.7‐FINAL‐14Nov2018‐WMS.pdf (accessed before 14 December 2018). ">GOLD 2019</a>), each of which may impact exacerbation frequency or severity. </p> <p>Inhaled corticosteroids have been available for asthma since the late 1970s, but it is unlikely that they were used by participants with chronic bronchitis in trials before 1990. In most of the other studies, ICS treatment was allowed. In the present review, we divided the studies into whether cotreatment with ICS was allowed, not allowed, or unclear (<a href="./references#CD001287-fig-0017" title="">Analysis 1.9</a>). There was no significant subgroup difference (P = 0.44), suggesting that the effect of mucolytics is not affected by ICS use. The nature of reporting of the studies did not allow us to stratify by use of measures mentioned previously that may reduce exacerbations. </p> <p>The trend in the likelihood that participants in control groups would be exacerbation‐free is 38% in pre‐1990 studies, 52% between 1990 and 2000, 42% from 2000 to 2009, and 29% from 2010 onwards (derived from <a href="./references#CD001287-fig-0010" title="">Analysis 1.2</a>). These findings suggest that up to 40% of study participants with COPD will have an exacerbation. One interpretation is that more recent studies show a trend toward improvement in overall care, but this needs follow‐up. </p> </section> </section> <section id="CD001287-sec-0104"> <h3 class="title" id="CD001287-sec-0104">Quality of the evidence</h3> <p>We graded all pooled outcomes as moderate, indicating that the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different (<a href="./full#CD001287-tbl-0001">summary of findings Table for the main comparison</a>). Our confidence in the pooled estimates was reduced by several considerations. Most outcomes were both clinically diverse and statistically heterogeneous.. Trials used a variety of types and doses of mucolytic, were conducted over two months to three years, and recruited populations with different baseline severity of COPD. Many were conducted in the 1980s and 1990s, at which time standard definitions and standard treatment for COPD differed from today. Subgroup analysis applied to our primary outcome of exacerbations explained some, but not all, the statistical heterogeneity. Therefore all outcomes, with the exception of mortality, were downgraded for inconsistency. </p> <p>Although we had concerns about the conduct methods used for some of the included trials, including uncertainty about methods of allocation concealment and blinding, we did not downgrade any outcome for risk of bias, as the trials about which we had greatest concern were generally of low weight in the meta‐analyses. We also judged 13 studies to be at high risk of attrition bias due to high or unbalanced dropout. To explore this further, we conducted a post hoc sensitivity analysis on our primary outcome (participants with no exacerbations during follow‐up). Removal of studies considered to be at high risk of attrition bias had a minimal impact on the pooled effect estimate. </p> <p>Funnel plots for days of disability and FEV₁ outcomes (<a href="./full#CD001287-fig-0001">Figure 1</a> and <a href="./full#CD001287-fig-0002">Figure 2</a>) suggest a possible small‐study effect (i.e. missing small negative trials). Removing the small positive trials from the analyses had minimal impact on the pooled result; therefore we did not downgrade for this reason. Furthermore, a funnel plot for the primary outcome participants with no exacerbation appeared symmetrical, giving no indication of publication bias (<a href="#CD001287-fig-0008">Figure 8</a>). </p> <p>We considered a downgrade for imprecision for health‐related quality of life, but although the confidence interval includes no difference, both ends lie within the MCID for SGRQ, and thus we are reasonably confident that mucolytics do not have a substantial impact on quality of life. However, we did downgrade mortality for imprecision, as the confidence interval of the pooled effect estimate includes both important harm and benefit of the intervention. </p> <p>Finally, although we considered indirectness on the basis of the age of some of the included studies, we did not judge our concerns to be sufficiently serious to warrant a downgrade. </p> </section> <section id="CD001287-sec-0105"> <h3 class="title" id="CD001287-sec-0105">Potential biases in the review process</h3> <p>The subgroup analysis by decade of publication is post hoc for updates from 2012 onward and should be interpreted with caution. In a few analyses, we have imputed standard deviations. When this has been done, it has been done conservatively and in accordance with accepted practices. This could have narrowed the confidence intervals for individual studies, thus increasing heterogeneity. Furthermore, the approach that we used may tend to overestimate the number of exacerbations per year in both groups, as more occur during the winter months, when many of these studies were performed. </p> <p>Despite the use of a consistent approach, slight rounding errors may have been introduced by the calculation of exacerbation rates per participant per month from study data to fit into earlier versions of RevMan that allowed only two decimal points. Furthermore, we decided to remove the meta‐analysis for this outcome for the 2019 update, as we made a post hoc decision that this analysis is less robust than the dichotomous exacerbation outcome. Reasons include likely skew, high heterogeneity, and reliance on calculated/imputed data for this analysis. </p> </section> <section id="CD001287-sec-0106"> <h3 class="title" id="CD001287-sec-0106">Agreements and disagreements with other studies or reviews</h3> <p>In addition to this review, we have identified five other systematic reviews of the effects of NAC in chronic bronchitis/COPD. Our results are consistent with these findings. The largest of these reviews included 13 randomised controlled trials (RCTs) (<a href="./references#CD001287-bbs2-0065" title="CazzolaM , CalzettaL , PageC , JardimJ , ChuchalinAG , RoglianiP , et al. Influence of N‐acetylcysteine on chronic bronchitis or COPD exacerbations: a meta‐analysis. European Respiratory Review2015;24(137):451‐61. ">Cazzola 2015</a>). This meta‐analysis reported that patients treated with NAC had significantly and consistently fewer exacerbations of chronic bronchitis or COPD (risk ratio (RR) 0.75, 95% CI 0.66 to 0.84). </p> <p>The second review demonstrated that individuals treated with NAC were more likely to remain exacerbation‐free (OR 1.56, 95% CI 1.37 to 1.77), with a number needed to treat for an additional beneficial outcome (NNTB) of 6 (95% CI 5 to 9) (<a href="./references#CD001287-bbs2-0085" title="SteyC , SteurerJ , BachmannS , MediciTC , TramerMR . The effect of oral N‐acetylcysteine in chronic bronchitis: a quantitative systematic review. European Respiratory Journal2000;16(2):253‐62. ">Stey 2000</a>). Participants were more likely to report improvement in symptoms with NAC (OR 1.78, 95% CI 1.54 to 2.05) than with placebo. The third review analysed nine trials that had been included in both <a href="./references#CD001287-bbs2-0085" title="SteyC , SteurerJ , BachmannS , MediciTC , TramerMR . The effect of oral N‐acetylcysteine in chronic bronchitis: a quantitative systematic review. European Respiratory Journal2000;16(2):253‐62. ">Stey 2000</a> and this Cochrane review, and confirmed a significant effect on exacerbations (standardised mean difference (SMD) ‐1.37, 95% CI ‐1.5 to ‐1.25) (<a href="./references#CD001287-bbs2-0070" title="GrandjeanEM , BerthetPH , RuffmanR , LeuenbergerPH . Efficacy of oral long‐term N‐acetylcysteine in chronic bronchopulmonary disease: a meta‐analysis of published double‐blind, placebo‐controlled clinical trials. Clinical Therapeutics2000;22(2):209‐20. ">Grandjean 2000</a>). A meta‐analysis published in 2017 investigating the effects of NAC on exacerbations of COPD showed that both high‐dose (RR 0.90, 95% CI 0.82 to 0.996) and low‐dose (RR 0.83, 95% CI 0.69 to 0.99) NAC reduced COPD exacerbations (<a href="./references#CD001287-bbs2-0068" title="FowdarK , ChenH , HeZ , ZhangJ , ZhongX , ZhangJ , et al. The effect of N‐acetylcysteine on exacerbations of chronic obstructive pulmonary disease: a meta‐analysis and systematic review. Heart and Lung2017;46(2):120‐8. ">Fowdar 2017</a>). Therefore, the review concluded that long‐term therapy may reduce risk of COPD exacerbation, which is in agreement with our findings. </p> <p>The fifth review investigated the use of mucolytics and antioxidants for COPD (<a href="./references#CD001287-bbs2-0077" title="LiX , SunH , LiuC , KangJ . Mucolytic and antioxidant agents for exacerbations of chronic obstructive pulmonary disease: a meta‐analysis. Chinese Journal of Tuberculosis and Respiratory Diseases2015;38(8):600‐6. ">Li 2015</a>; abstract only available in English). The review includes 10 RCTs and reports that mucolytics and antioxidants reduce the number of exacerbations per patient per year compared to placebo, and that high‐dose NAC may be more effective than low‐dose, although a test for subgroup differences was not reported in the abstract. </p> <p>The analyses in this review suggest that mucolytics might, in addition, have an effect on duration and severity of exacerbations that do occur, and on the likelihood of taking antibiotics. Data from four studies suggest that mucolytics are associated with decreased hospitalisation rates. It would be helpful if future studies looked at this outcome, as this is where most costs associated with more severe disease are incurred. Few other pharmacological treatments have been shown to reduce hospitalisation: an immunomodulatory agent OM‐85 BV, or Broncho‐Vaxom (<a href="./references#CD001287-bbs2-0066" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719‐24. ">Collet 1997</a>), was shown to reduce the number of hospital admissions in COPD, even though it did not affect the number of exacerbations. </p> <p>Researchers performed a retrospective cost‐effectiveness analysis of NAC in chronic bronchitis that was based on direct costs of NAC treatment, management of an acute exacerbation, and indirect costs of sick leave (<a href="./references#CD001287-bbs2-0071" title="GrandjeanEM , BerthetPH , RuffmanR , LeuenbergerPH . Cost‐effectiveness analysis of oral N‐acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacology Research2000;42(1):39‐50. ">Grandjean 2000a</a>). Results suggest that costs of treatment and non‐treatment were equal at the point of a reduction of 0.6 exacerbations per six‐month period. In our review, a reduction of about 0.18 per six‐month period suggested that it would not be cost‐effective to treat everyone with COPD with mucolytics. </p> <p><a href="./references#CD001287-bbs2-0003" title="BachhAA , ShahNN , BhargavaR , AhmadZ , PandeyDK , DarKA . Effect of oral N‐acetylcysteine in COPD ‐ a randomised controlled trial. JK‐Practitioner2007;14(1):12‐6. ">Bachh 2007</a> and colleagues from India estimated the cost of prophylactic NAC therapy to be INR 6000 (USD 120), whereas a short course of oral corticosteroids (OCSs) and antibiotics would cost INR 200 (USD 4). ICSs are also expensive. As the burden of COPD over coming decades is going to disproportionately affect developing nations, the relative costs of each strategy are important to determine. </p> <p>Several national and international guidelines make recommendations about the use of mucolytics. In a recent North American guideline on treatments to prevent COPD exacerbations, NAC was suggested for patients with moderate or severe COPD and a history of two or more exacerbations in the previous two years (evidence grade 2B ‐ weak recommendation; moderate‐quality evidence; <a href="./references#CD001287-bbs2-0067" title="CrinerGJ , BourbeauJ , DiekemperRL , OuelletteDR , GoodridgeD , HernandezP , et al. Prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest2015;147(4):883‐93. ">Criner 2015</a>). Furthermore, carbocysteine was suggested (ungraded consensus‐based statement) for patients still having exacerbations in spite of maximal therapy provided to reduce exacerbations. This is consistent with the more recent Joint American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for prevention of exacerbations, which gives a conditional recommendation for the use of mucolytics in patients with moderate to severe airflow obstruction and frequent exacerbations despite optimal therapy, based on low‐quality evidence (<a href="./references#CD001287-bbs2-0087" title="WedzichaJA , CalverleyPMA , AlbertRK , AnzuetoA , CrinerGJ , HurstJR , et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal2017;50(3):pii: 1602265. ">Wedzicha 2017</a>). The 2019 update of the global COPD guidelines states that NAC may have a role in the treatment of patients with recurrent exacerbations (evidence grade B ‐ moderate‐quality evidence), and that carbocysteine or NAC may reduce exacerbations in patients not taking inhaled steroids (grade B) (<a href="./references#CD001287-bbs2-0069" title="Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. goldcopd.org/wp‐content/uploads/2018/11/GOLD‐2019‐v1.7‐FINAL‐14Nov2018‐WMS.pdf (accessed before 14 December 2018). ">GOLD 2019</a>). COPD‐X guidelines give a stronger recommendation in favour of high‐dose oral NAC (<a href="./references#CD001287-bbs2-0089" title="YangIA , BrownJL , GeorgeJ , JenkinsS , McDonaldCF , McDonaldV , et al. The COPD‐X Plan: Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease. Version 2.53. copdx.org.au/wp‐content/uploads/2018/11/COPDX‐V2‐55‐Aug‐2018.pdf (accessed before 13 December 2018). ">Yang 2018</a>), and UK National Institute for Health and Care Excellence (NICE) guidelines suggest use in patients with chronic cough productive of sputum and continued only if there is symptomatic improvement (<a href="./references#CD001287-bbs2-0079" title="National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. www.nice.org.uk/guidance/ng115 (accessed before 14 December 2018). ">NICE 2018</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001287-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.11 Days of disability per participant per month." data-id="CD001287-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.11 Days of disability per participant per month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.13 FEV₁ at end of study." data-id="CD001287-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.13 FEV₁ at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update." data-id="CD001287-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001287-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Mucolytic versus placebo, outcome: 1.1 Participants with no exacerbations in study period." data-id="CD001287-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mucolytic versus placebo, outcome: 1.1 Participants with no exacerbations in study period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="In the control group, 39 of 100 people were free from exacerbations over 9 months (represented by green faces) compared with 52 (95% CI 49 to 55) of 100 for the mucolytic group (represented by green plus yellow faces)." data-id="CD001287-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>In the control group, 39 of 100 people were free from exacerbations over 9 months (represented by green faces) compared with 52 (95% CI 49 to 55) of 100 for the mucolytic group (represented by green plus yellow faces). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Mucolytic versus placebo, outcome: 1.2 Participants with no exacerbation by decade; double‐blind trials only." data-id="CD001287-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mucolytic versus placebo, outcome: 1.2 Participants with no exacerbation by decade; double‐blind trials only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.1 Participants with no exacerbations in study period." data-id="CD001287-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Mucolytic versus placebo, outcome: 1.1 Participants with no exacerbations in study period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 1 Participants with no exacerbations in study period." data-id="CD001287-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 1 Participants with no exacerbations in study period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 2 Participants with no exacerbation by decade, double‐blind trials only." data-id="CD001287-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 2 Participants with no exacerbation by decade, double‐blind trials only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 3 Participants with no exacerbations in the study period ‐ winter treatment only." data-id="CD001287-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 3 Participants with no exacerbations in the study period ‐ winter treatment only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 4 Participants with no exacerbations in study period ‐ by dose or type of mucolytic." data-id="CD001287-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 4 Participants with no exacerbations in study period ‐ by dose or type of mucolytic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 5 Participants with no exacerbations in study period ‐ by FEV₁." data-id="CD001287-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 5 Participants with no exacerbations in study period ‐ by FEV₁. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 6 Participants with no exacerbations in study period ‐ by study duration." data-id="CD001287-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 6 Participants with no exacerbations in study period ‐ by study duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 7 Participants with no exacerbations in study period ‐ by country." data-id="CD001287-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 7 Participants with no exacerbations in study period ‐ by country. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 8 Participants with no exacerbations in study period ‐ by history of exacerbation." data-id="CD001287-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 8 Participants with no exacerbations in study period ‐ by history of exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 9 Participants with no exacerbations in study period ‐ by ICS use." data-id="CD001287-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 9 Participants with no exacerbations in study period ‐ by ICS use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0018"> <p> <div class="table" id="CD001287-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean mucolytic group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean difference [95% CI]</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allegra 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.04 [‐0.06, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Babolini 1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20 [‐0.24, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Boman 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.12 [‐0.20, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Borgia 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.10 [‐0.22, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Castiglioni 1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.10 [‐0.14, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cremonini 1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.46 [‐0.62, ‐0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decramer 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.01 [‐0.03, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fukuchi 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 [‐0.02, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grassi 1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.13 [‐0.22, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grassi 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.29 [‐0.45, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grillage 1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.02 [‐0.07, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hansen 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.05 [‐0.11, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jackson 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.02 [‐0.07, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malerba 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.01 [‐0.03, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McGavin 1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.10 [‐0.21, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meister 1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.05 [‐0.10, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meister 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.04 [‐0.08, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moretti 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.05 [‐0.10, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nowak 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.03 [‐0.05, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olivieri 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.15 [‐0.25, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parr 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.03 [‐0.07, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pela 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.13 [‐0.22, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rasmussen 1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.01 [‐0.09, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schermer 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 [‐0.00, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tse 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.06 [‐0.15, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worth 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.08 [‐0.13, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.03 [‐0.04, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.03 [‐0.05, ‐0.01]</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 10 Number of exacerbations per participant per month. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0018">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001287-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-11.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 11 Days of disability per participant per month." data-id="CD001287-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 11 Days of disability per participant per month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 12 Days on antibiotics per participant per month." data-id="CD001287-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 12 Days on antibiotics per participant per month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-13.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 13 FEV₁ at end of study." data-id="CD001287-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 13 FEV₁ at end of study.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 14 Percent predicted FEV₁." data-id="CD001287-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 14 Percent predicted FEV₁.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 15 PEFR at end of study." data-id="CD001287-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 15 PEFR at end of study.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 16 FVC at end of study." data-id="CD001287-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 16 FVC at end of study.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 17 Adverse effects." data-id="CD001287-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 17 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 18 Hospitalisation during study period." data-id="CD001287-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 18 Hospitalisation during study period.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 19 Death during study period." data-id="CD001287-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 19 Death during study period.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 20 Health‐related quality of life (total score St. George's Respiratory Questionnaire)." data-id="CD001287-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 20 Health‐related quality of life (total score St. George's Respiratory Questionnaire). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mucolytic versus placebo, Outcome 21 Health‐related quality of life (total score COPD Assessment Test)." data-id="CD001287-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Mucolytic versus placebo, Outcome 21 Health‐related quality of life (total score COPD Assessment Test). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic thiol donor versus placebo, Outcome 1 Participants with no exacerbations in the study period." data-id="CD001287-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Systemic thiol donor versus placebo, Outcome 1 Participants with no exacerbations in the study period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0031"> <p> <div class="table" id="CD001287-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean mucolytic group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean difference [95% CI]</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ekberg‐Jansson 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Systemic thiol donor versus placebo, Outcome 2 Number of exacerbations per participant per month. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0031">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001287-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic thiol donor versus placebo, Outcome 3 Days of disability per participant per month." data-id="CD001287-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Systemic thiol donor versus placebo, Outcome 3 Days of disability per participant per month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001287-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/urn:x-wiley:14651858:media:CD001287:CD001287-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_t/tCD001287-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic thiol donor versus placebo, Outcome 4 Adverse effects." data-id="CD001287-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Systemic thiol donor versus placebo, Outcome 4 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/media/CDSR/CD001287/image_n/nCD001287-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001287-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Mucolytic compared to placebo for chronic bronchitis or chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mucolytic compared to placebo for chronic bronchitis or chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> chronic bronchitis or COPD<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> mucolytic<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes*</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects† (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mucolytic</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with no exacerbations in study period</b> </p> <p>Follow‐up: 8.8 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>386 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>521 per 1000<br/> (495 to 545) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 1.73<br/> (1.56 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6723<br/> (28 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generally larger effects in earlier studies of mucolytics in chronic bronchitis and smaller effects in more recent studies in COPD </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days of disability per participant per month</b> </p> <p>Follow‐up: 8.3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of disability per participant per month was 1.57 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.43 days lower<br/> (0.56 lower to 0.30 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2259<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life (total score SGRQ)</b> </p> <p>Scale from 1 to 100; lower scores indicate better quality of life</p> <p>Follow‐up: 14.1 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ total score was 39.02 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.37 lower<br/> (2.85 lower to 0.11 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2721<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID for SGRQ is 4 points</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation during study period</b> </p> <p>Follow‐up: 16.6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000<br/> (107 to 171) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.68<br/> (0.52 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1833<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV</b> ₁<b>at end of study</b> </p> <p>Follow‐up: 14.5 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean FEV₁ at end of study was 1.50 L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.04 L higher<br/> (0.01 higher to 0.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3473<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID for FEV₁ in COPD is approximately 0.1 L (<a href="./references#CD001287-bbs2-0076" title="JonesPW , BeehKM , ChapmanKR , DecramerM , MahlerDA , WedzichaJA . Minimal clinically important differences in pharmacological trials. American Journal of Respiratory and Critical Care Medicine2013;189(3):250‐5. ">Jones 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: 8.2 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>235 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000<br/> (185 to 224) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.84<br/> (0.74 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7264<br/> (24 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death during study period</b> </p> <p>Follow‐up: 13.3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (5 to 20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.98<br/> (0.51 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3527<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 deaths on mucolytics and 19 on placebo</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Follow‐up was calculated as a weighted mean duration.<br/> †<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>CI: confidence interval; COPD: chronic obstructive pulmonary disease; FEV₁: forced expiratory volume in one second; MCID: minimally clinically important difference; MD: mean difference; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio; SGRQ: St. George's Respiartory Questionaire; WMD: weighted mean duration. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Statistical and clinical heterogeneity identified. Downgraded once for inconsistency. </p> <p><sup>b</sup>Funnel plots suggest small negative trials under‐represented (<a href="./full#CD001287-fig-0001">Figure 1</a>; <a href="./full#CD001287-fig-0002">Figure 2</a>). However, removing the positive small trials from the analysis had little impact on the pooled estimate. No downgrade. </p> <p><sup>c</sup>Confidence interval includes possibility of no difference between groups, but both ends of confidence interval lie within MCID. No downgrade for imprecision. </p> <p><sup>d</sup>Confidence interval includes possibility of both an important increase or reduction in deaths. Downgraded once for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Mucolytic compared to placebo for chronic bronchitis or chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001287-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study<br/> duration<br/> (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean<br/> age<br/> (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>COPD<br/> severity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0001" title="AllegraL , CordaroCI , GrassiC . Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double‐blind, placebo‐controlled trial. Respiration1996;63:174‐80. ">Allegra 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbocysteine‐lysine 2.7 g daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diary of scores, exacerbations, time to first exacerbation, duration of exacerbation, days on antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0002" title="Multicenter Study Group. Long‐term oral acetylcysteine in chronic bronchitis. A double‐blind controlled study. European Journal of Respiratory Disease1980;61(111 Suppl):93‐108. ">Babolini 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, symptom scores, global assessments by patients and physicians, AEs, days on antibiotics </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0003" title="BachhAA , ShahNN , BhargavaR , AhmadZ , PandeyDK , DarKA . Effect of oral N‐acetylcysteine in COPD ‐ a randomised controlled trial. JK‐Practitioner2007;14(1):12‐6. ">Bachh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, hospital admissions, lung function, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0004" title="BomanG , BackerU , LarssonS , MelanderB , WahlanderL . Oral acetylcysteine reduces exacerbation rate in chronic bronchitis; report of a trial organized by the Swedish Society for Pulmonary Diseases. European Journal of Respiratory Disease1983;64:405‐15. ">Boman 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe<br/> to very<br/> severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, sick leave due to exacerbation, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0005" title="BontognaliE . Clinical effectiveness and tolerance of cithiolone in the prophylaxis of acute infective exacerbations in patients suffering from chronic bronchitis. Acta Therapeutica1991;17:155‐62. ">Bontognali 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cithiolone 400 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo for 1 month followed by 400 mg once daily for a further 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, duration of acute exacerbations, FEV₁, FVC, sputum viscosity, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0006" title="BorgiaM , SepeN , Ori‐BelomettiM , BorgiaR . Comparison between acetylcysteine and placebo in the long term treatment of chronic bronchitis [Confronto tra acetilcisteina e placebo nel trattamento a lungo termine della bronchite cronica]. Gazzetta Medica Italiana1981;140:467‐72. ">Borgia 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, lung function, symptom scores, clinical assessments, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0007" title="CastiglioniCL , GramoliniC . Effect of long‐term treatment with sobrerol on the exacerbations of chronic bronchitis. Respiration1986;50:202‐17. ">Castiglioni 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sobrerol 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation rate, consumption of antibiotics, clinical signs, laboratory data, lung function, global assessment by investigator and patient, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0008" title="CeglaUH . Long‐term treatment of chronic bronchitis for two years with ambroxol (Mucosolvan) retard capsules. Results of a double blind trial including 180 patients [Langzeittherapie uber 2 Jahre mit Ambroxol (Mucosolvan) Retardkapseln bei Patienten mit chronischer Bronchitis. Ergebnisse einer Doppelblindstudie an 180 Patienten]. Praxis Klinik der Pneumologie1988;42:715‐21. ">Cegla 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ambroxol retard 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, days sick (off work, in hospital), patient symptoms by diary card, lung function, extra medication use, assessment by investigator and patient, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0009" title="CremoniniC , SpadaE , CelliniF , CioniR , GiovanniniM , PerriG , et al. I farmaci attivi sul muco nel trattamento di fondo della bronchite cronica [Pharmacotherapy which acts on mucus in long‐term treatment of chronic bronchitis]. La Clinica Terapeutica1986;116:121‐9. ">Cremonini 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Letosteine 50 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, days off sick, lung function</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0010" title="CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776. CalverleyPMA , PageC , Dal NegroRW , FontanaG , IversenM , CiceroAF , et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49. Dal NegroRW , IversenM , CalverlyPM . Efficacy and safety of erdostein in COPD: results of a 12‐month prospective, multinational study. European Respiratory Journal2015;46:PA1495. Dal NegroRW , WedzichaJA , IversenM , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal2017;50(4):1700711. [DOI: 10.1183/13993003.00711‐2017] Dal NegroRW , WedzichaJA , IversenMI , FontanaG , PageC , CiceroAF , et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675. ">Dal Negro 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 European countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erdosteine 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of acute exacerbations, spirometry parameters, COPD symptoms, QoL, safety and tolerability of erdosteine </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0011" title="DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelP , et al. Double blind, randomized, two‐way crossover, pilot study to assess the effect of high dose N‐acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447. DeBackerJ , VosW , VanHolsbekeC , VinchurkarS , ClaesR , ParizelPM , et al. Effect of high‐dose N‐acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2013;8:569‐79. ">De Backer 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Belgium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spirometry, PEFR, raw, NO, specific airway resistance from plethysmography, CT to look at airway geometry, serum glutathione, enzymes, SGRQ, ABG </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0012" title="DecramerM , Rutten‐van MolkenM , DekhuijzenPN , TroostersT , vanHerwaardenC , PellegrinoR , et al. Effects of N‐acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost‐Utility Study, BRONCUS): a randomised placebo‐controlled trial. Lancet2005;365(9470):1552‐60. ">Decramer 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lung function, exacerbation rate, QoL, cost utility</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0013" title="Ekberg‐JanssonA , LarsonM , MacNeeW , TunekA , WahlgrenL , WoutersEFM , et al. N isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. European Respiratory Journal1999;13(4):829‐34. ">Ekberg‐Jansson 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>637</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild,<br/> moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIC 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to first exacerbation, exacerbation rate, days sick (judged by patients and investigators), lung function, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0014" title="FukuchiY , TatsumiK , InoueH , SakataY , ShibataK , MiyagishiH , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. International Journal of Chronic Obstructive Pulmonary Disease2016;11:831‐8. IchinoseM , FukuchiY , TatsumiK , InoueH , AraiT , ShibataK , et al. Prevention of COPD exacerbation by lysozyme: a double‐blind, randomized, placebo‐controlled study. European Respiratory Journal2015;46:PA4359. ">Fukuchi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate,<br/> severe to<br/> very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lysozyme 90 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation rate, time to first exacerbation, lung function, CAT</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0015" title="GrassiC , MorandiniGC . A controlled trial of intermittent oral acetylcysteine in the long‐term treatment of chronic bronchitis. European Journal of Clinical Pharmacology1976;9:393‐6. ">Grassi 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, clinical symptoms, sputum characteristics, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0016" title="GrassiC , CasaliL , CiacciaA , et al. [Terapia intervallare con l'associazione carbocisteina‐sobrerolo nella profilassi delle riacutizzazioni della bronchite cronica]. Italian Journal of Chest Disease1994;48:17‐26. ">Grassi 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbocysteine 1125 mg plus sobrerol 180 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo or alternating active‐placebo for 10 days each</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, symptoms, sputum characteristics</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0017" title="GrillageM , Barnard‐JonesK . Long‐term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. British Journal of Clinical Practice1985;39(10):395‐8. ">Grillage 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Britain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbocysteine 750 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, lung function, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0018" title="HansenNC , SkriverA , Brorsen‐RiisL , BalsløvS , EvaldT , MaltbaekN , et al. Orally administered N‐acetylcysteine may improve general well‐being in patients with mild chronic bronchitis. Respiratory Medicine1994;88:531‐5. ">Hansen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, subjective symptom scores, global well‐being, lung function, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0019" title="JacksonIM , BarnesJ , CookseyP . Efficacy and tolerability of oral acetylcysteine (fabrol) in chronic bronchitis: a double‐blind placebo controlled trial. Journal of International Medical Research1984;12:198‐206. ">Jackson 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Great Britiain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations, subjective symptoms, clinical signs, radiological appearance, global well being, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0020" title="JohnsonK , McEvoyCE , NaqviS , WendtC , ReilkoffRA , KunisakiKM , et al. High‐dose oral N‐acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo‐controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11:799‐807. ">Johnson 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 1800 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change SGRQ, CBSAS, SF‐36; post‐bronchodilator lung function</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0021" title="MalerbaM , PonticelloA , RadaeliA , BensiG , GrassiV . Effect of twelve‐months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double‐blind, randomized, multi‐center, placebo‐controlled study (the AMETHIST trial). Pulmonary Pharmacology and Therapeutics2004;17(1):27‐34. ">Malerba 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ambroxol 75 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation over first 6 months (winter period) and at 12 months, cough intensity and frequency, difficult expectoration, dyspnoea, days on antibiotics, number of working days lost </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0022" title="British Thoracic Society Research Committee. Oral N‐acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax1985;40(11):832‐5. ">McGavin 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe<br/> to very<br/> severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Great Britain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, days of antibiotics, days in bed, FEV₁, VC, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0023" title="MeisterR . Long‐term therapy with acetylcysteine retard tablets in patients with chronic bronchitis: a double‐blind, placebo controlled study. Unpublished source1986. ">Meister 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, days sick, concomitant treatment, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0024" title="BeehK‐M , BeierJ , CandlerH , WittigT . Effect of ELOM‐080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype ‐ a post‐hoc analysis of a randomized, double‐blind, placebo‐controlled clinical trial. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2877‐84. MeisterR , WittigT , BeuscherN , deMeyC . Efficacy and tolerability of myrtol standardized in long‐term treatment of chronic bronchitis. A double‐blind, placebo‐controlled study. Study Group Investigators. Arzneimittelforschung1999;49(4):351‐8. ">Meister 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myrtol 300 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, number of exacerbations requiring antibiotics, well‐being, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0025" title="MorettiM , BottrighiP , DallariR , DaPortoR , DolcettiA , GrandiP , et al. The effect of long‐term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Under Experimental and Clinical Research2004;30(4):143‐52. ">Moretti 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate,<br/> severe to<br/> very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erdosteine 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation frequency, duration, hospitalisation, lung function, 6MWT, SGRQ, pharmacoeconomic analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0026" title="NowakD , CaratiL , PirozynskiM . Long‐term administration of N‐acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal1999;14 Suppl:381S‐2S. ">Nowak 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, severity of exacerbations, time to first exacerbation, days sick, lung function, patient symptoms, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0027" title="OlivieriD , ZavattiniG , TomasiniG , DaniottiS , BonsignoreG , FerraraG , et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long‐term multicenter trial. Respiration1987;51 Suppl 1:42‐51. ">Olivieri 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild, moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ambroxol retard 75 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, course of antibiotics, days sick, FEV₁, VC, symptoms, auscultatory findings, physicians' and patients' global assessments, laboratory data, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0028" title="ParrGD , HuitsonA . Oral fabrol (oral n‐acetyl‐cysteine) in chronic bronchitis. British Journal of Diseases of the Chest1987;81(4):341‐8. ">Parr 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Great Britain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 200 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, days off work, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0029" title="PelaR , CalcagniAM , SubiacoS , IsidoriP , TubaldiA , SanguinettiCM . N‐acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration1999;66(6):495‐500. ">Pela 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate,<br/> severe to<br/> very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, exacerbation severity, days sick, patient preference, lung function</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0030" title="MorganEJ , PettyTL . Summary of the national mucolytic study. Chest1990;97(Suppl):24S‐7S. PettyTL . The national mucolytic study: results of a randomized, double‐blind, placebo‐controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest1990;97(1):75‐83. ">Petty 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate,<br/> severe to<br/> very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iodinated glycerol 30 mg 4 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Investigator assessment of symptoms, patient evaluation of symptoms and global assessment, frequency of bronchodilator use, number and duration of acute exacerbations, frequency of concomitant medications, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0031" title="RasmussenJB , GlennowC . Reduction in days of illness after long‐term treatment with N‐acetylcysteine controlled‐release tablets in patients with chronic bronchitis. European Respiratory Journal1988;1:351‐5. ">Rasmussen 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 300 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation, days sick evaluated by days on sick list and by patient diaries, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0032" title="RoyP , HaranA , SrinivasBN . Role of n‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication2013;45:S107. RoyP , HaranA , SrinivasBN , MjumdarP . Evaluation of effect of N‐acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences2014;3(1):95‐105. ">Roy 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptoms (cough, dyspnoea, sputum), lung function, haemoglobin levels, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0033" title="ChavannesN , SchermerT , WoutersEFM , FolgeringH . Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study. European Respiratory Journal2005;26 (S49):1356. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103:542‐51. ">Schermer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild, moderate,<br/> severe to<br/> very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rate of exacerbations, CRQ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0034" title="TseHN , RaiteriL , WongKY , NgLY , YeeKs , TsengCZS . Benefits of high‐dose N‐acetylcysteine to exacerbation‐prone patients with COPD. Chest2014;146(3):611‐23. TseHN , RaiteriL , WongKY , YeeKS , NgLY , WaiKY , et al. High‐dose N‐acetylcysteine in stable COPD: the 1‐year, double‐blind, randomized, placebo‐controlled HIACE study. Chest2013;144:106‐18. TseHN , WongKY , YeeKS , NgLY . The effect of high dose N‐acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: a double blinded randomized placebo controlled trial. European Respiratory Journal2012;40 Suppl 56:P2105. TseHN , WongKY , YeeKS , NgLY , WaiKY , LooCK , et al. The effect of high dose N‐acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease ‐ a one‐year, double blind, randomized, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2013;187:A2448. ">Tse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild, moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small airways parameters FEF<sub>25‐75%</sub>, FOT, IC, spirometry, exacerbation rate, dyspnoea, SGRQ, 6MWD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0035" title="WorthH , SchacherC , DethlefsenU . Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: a placebo‐controlled double‐blind trial. Respiratory Research2009;10(1):69. WorthH , SchacherC , DethlefsenU . Effects of concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: a placebo‐controlled double‐blind trial. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010; Vol. P538. ">Worth 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cineole 200 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations: number, severity, and duration, lung function, dyspnoea, SGRQ, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0036" title="XuX‐G , JiangZ‐Y , DuM‐J , YangY‐Q , JiangY‐C . Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N‐acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition2014;40(40):870‐4. ">Xu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol/fluticasone propionate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV₁ %/FVC, FEV₁ % predicted, PEF% daily variation change, PaO₂, PaCO₂</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0037" title="ZhengJP , KangJ , HuangSG , ChenP , YaoWZ , YangL , et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomised placebo‐controlled trial. Lancet2008;371(9629):2013‐8. ">Zheng 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate,<br/> severe to very severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbocysteine 500 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation rate, covariance‐adjusted exacerbation rate, QoL, lung function, arterial oxygen saturation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001287-bbs2-0038" title="PapiA , BrusselleG , SergioF , PannacciM , ZhengJ , CrinerG . Blood eosinophils and smoking history affect outcome with high dose N‐acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066. PapiA , ZhengJ , CrinerGJ , FabbriLM , CalverleyPMA . Impact of smoking status and concomitant medications on the effect of high‐dose N‐acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post‐hoc analysis of the PANTHEON study. Respiratory Medicine2019;147:37‐43. SergioF , PapiA , CrinerG , BrusselleG , CalverleyP , FabbriL , et al. Long term treatment with n‐acetylcysteine reduces moderate‐severe exacerbations of chronic obstructive pulmonary disease. Respirology2016;21:186. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease2013;10:164‐71. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. High‐dose N‐acetylcysteine in the prevention of COPD exacerbations: results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013. ZhengJP , WenFQ , BaiCX , WanHY , KangJ , ChenP , et al. Twice daily N‐acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double‐blind placebo‐controlled trial. Lancet Respiratory Medicine2014;2:187‐94. ">Zheng 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<br/> to severe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbation rate, exacerbation duration, time to first exacerbation, time to recurrent exacerbation, number of participants requiring systemic corticosteroids or antibiotics or SABA, SGRQ (Chinese version), lung function, AEs (including hospitalisation or death) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>6MWD: six‐minute walk distance; AEs: adverse events; CAT: COPD assessment test; CBSAS: Chronic Bronchitis Symptoms Assessment Scale; CRQ: chronic respiratory questionnaire; FEF<sub>25‐75%</sub>: forced expiratory flow at 25%‐75% of the pulmonary volume; FEV₁: forced expiratory volume in one second; FOT: forced oscillatory technique; FVC: forced vital capacity; IC: inspiratory capacity; NAC: N‐acetylcysteine; NIC: N‐isobutyrylcysteine; PaCO₂: partial pressure of carbon dioxide; PaO₂: partial pressure of oxygen; PEF: peak expiratory flow; QoL: quality of life; SABA: short‐acting beta‐agonist; SCMC‐Lys: carbocysteine lysine salt monohydrate; SF‐36:Short Form‐36 Health Survey; SGRQ: St. George's respiratory questionnaire; VC: vital capacity. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/full#CD001287-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001287-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mucolytic versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants with no exacerbations in study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.56, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.53, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Single‐blind/open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [1.76, 4.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants with no exacerbation by decade, double‐blind trials only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.53, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Before 1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [1.97, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 1990 to 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.50, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 2000 to 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.01, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 2010 onwards</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.03, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants with no exacerbations in the study period ‐ winter treatment only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [1.93, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3844</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [1.91, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Single‐blind/open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [1.49, 5.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participants with no exacerbations in study period ‐ by dose or type of mucolytic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.56, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 NAC 400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.98 [2.21, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 NAC 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.40, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 NAC 1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.95, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 NAC 3200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.14, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Carbocysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.13, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Other mucolytic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [1.64, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Participants with no exacerbations in study period ‐ by FEV₁ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.56, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Mean FEV₁ &gt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.62, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Mean FEV₁ ≤ 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.08, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Participants with no exacerbations in study period ‐ by study duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.56, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Duration ≤ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.62, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Duration &gt; 3 months and &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [1.91, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Duration ≥ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.98, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Participants with no exacerbations in study period ‐ by country <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.56, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Italian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [2.06, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Rest of world</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.25, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Participants with no exacerbations in study period ‐ by history of exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.56, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Exacerbation history requirement for inclusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.32, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Exacerbation history not a requirement for inclusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [1.85, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Participants with no exacerbations in study period ‐ by ICS use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.56, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 ICS allowed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.46, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 ICS not allowed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.49, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 ICS unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.48, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Number of exacerbations per participant per month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Days of disability per participant per month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.56, ‐0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Days on antibiotics per participant per month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐0.76, ‐0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 FEV₁ at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Single‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.10, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Percent predicted FEV₁ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.79 [1.97, 7.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐4.72, 4.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Single‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐4.02, 5.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 No blinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.31 [11.83, 22.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 PEFR at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 FVC at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.00, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.74, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Hospitalisation during study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.52, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Death during study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.51, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Health‐related quality of life (total score St. George's Respiratory Questionnaire) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.37 [‐2.85, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Health‐related quality of life (total score COPD Assessment Test) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mucolytic versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001287-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Systemic thiol donor versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants with no exacerbations in the study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.74, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of exacerbations per participant per month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Days of disability per participant per month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.82, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.98, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Systemic thiol donor versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001287.pub6/references#CD001287-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001287.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001287-note-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001287-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001287-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD001287-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001287-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001287-note-0001">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001287-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001287\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001287\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001287\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001287\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001287\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001287.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001287.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001287.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001287.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001287.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714960971"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001287.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714960975"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001287.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7b723b429368',t:'MTc0MDcxNDk2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 